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Abstract 
 
Entosis describes a form of emperipolesis, where one cell invades a host cell.  
Emperipolesis can result in death, division or release of the internalised cell. 
Preliminary data demonstrates that entosis and release of CD4+T-cells occurs within 
primary hepatocytes and hepatoma cell lines.  
This study focuses on defining the environment and stimuli necessary to induce T-
cell release following entosis. A 7-Day release assay was optimised for measuring 
CD4+T-cell release following T-cell-hepatoma co-culture and entosis. Flow cytometry 
was then used to quantify the release of T-cells from HepG2-CD81 and Huh-7 cell 
lines in response to various stimuli, doses and incubation times.  
Results indicated that the majority of stimuli and dose responses were not 
responsible for inducing a higher or lower %T-cell release. Co-cultures also 
demonstrated a significantly higher %T-cell release from HepG2-CD81s at 2 hour 
compared to 24 hour incubations in treated and untreated co-cultures. Following 
optimisation of this release assay, the study concludes that further work is required to 
investigate the conditions which induce entosis and release of T-cells from hepatoma 
cell lines. Understanding the purpose and cause of T-cell entosis and release in the 
liver may lead to its therapeutic manipulation to prevent liver inflammation and 
diseases such as hepatitis.  
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1. Introduction 
1.1. The architecture & function of the liver 
 
The liver is the largest organ in the human body, which contains the biggest reticulo-
endothelial cell network(1, 2). Its functions include glycogen storage, detoxification, 
hormone production, digestion and metabolism(2). 80% of the liver is composed of 
parenchymal cells, otherwise known as hepatocytes. Other types of liver cells are 
demonstrated in Table 1. The architecture of the liver including the parenchymal and 
non-parenchymal cells is demonstrated by Figure 1. 
 Type of cell Function/definition 
Parenchymal cells Hepatocytes  Detoxification of drugs 
 Protein synthesis and 
storage 
 Carbohydrate and fat 
metabolism 
Non-parenchymal cells Sinusoidal endothelial 
cells 
 Removal of smaller 
particles from the 
circulation 
Kupffer cells  Intravascular tissue 
macrophages – removal 
large particles from 
circulation 
Hepatic stellate cells  Storage of Vitamin A 
PiT-cells   NK cells located beneath 
endothelial cells and 
fibroblasts 
Hepatic dendritic cells  Phagocytosis & release of 
cytokines in response to 
TLR stimulation 
NKT-cells  Antitumor/antiviral roles 
Biliary epithelial cells  Contribution to bile 
production & 
transportation of bile into 
gall bladder/intestine  
 
Table 1- Demonstration of parenchymal and non-parenchymal cell types and 
their function within the liver(2, 3). 
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Figure 1 - Architecture of cells within a liver lobule. The vascular bundles 
known as portal tracts contain the portal vein, bile duct and arteriole. Blood 
travels from the portal tracts through sinusoids which exist between 
hepatocytes. The sinusoids contain a population of macrophages called 
kupffer cells.(1) 
 
As well as metabolic functions, the liver also performs unique immunological roles, 
and is involved in maintaining peripheral tolerance as well as protecting against 
harmful pathogens(4).  
1.2. The liver immune system & hepatic T-cells 
 
The blood from the gastrointestinal tract is rich in nutrients, harmless food antigens 
and pathogens that have breached the intestinal barrier(2). This blood passes 
through the liver via the portal vein, allowing hepatocytes to metabolise specific 
substances, whilst also exposing them to microbial antigens(1, 2). As well as this 
consistent antigen exposure, the liver is also exposed to cytokine-rich blood from the 
spleen and metabolite-rich blood from the systemic artery(2). This puts constant 
pressure on the liver to induce tolerance or immunity(1, 2, 4). 
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1.2.1. Liver immune cells 
 
The sinusoidal endothelium is fenestrated and lacks a basement membrane, allowing 
blood, kupffer cells, DC’s and lymphocytes (including T-cells) to pass from the 
sinusoids into the space of Disse (sub-endothelial space), where they gain direct 
access to hepatocytes(1). 
Kupffer cells are phagocytic liver macrophages which reside in hepatic sinusoids and 
play a role in both tolerance, (by suppressing T-cell activation), and immunity, (by 
causing T-cell proliferation and cytokine synthesis)(1).  
Pit Cells (PCs) recruit T-cells via cytokine/chemokine cascades. PCs release IFN-ɤ 
which induces CXCL9 secretion via hepatocytes and LSECs (Liver sinusoidal 
endothelial cells), promoting T-cell recruitment and immunity(1). NKT-cells are also 
abundant in the liver, and are involved in immunity over tolerance(1, 2, 5). 
 LSECs engulf and present exogenous antigen on MHCII molecules which interact 
with naïve CD4+T-cells migrating into the liver(6). Unlike liver dendritic cells, it is 
unknown whether LSECs are able to prime CD4+T-cells(6). 
 The location of immune cells found in the sinusoidal space is illustrated in Figure 2. 
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Figure 2- Immune cells present within the sinusoidal space can make contact 
with hepatocytes via the Space of Disse, which is where hepatic lymph 
originates from. LSECs line the fenestrated endothelium. Sinusoids contain 
Kupffer cells, lymphocytes, PCs and iDCs(1). 
 
1.2.2. Hepatic T-cells 
 
Studies show that liver CD4+ T-cells are functionally distinct compared to those in the 
spleen as they produce higher levels of IL-4, IL-5, IL-10 and IFN-ɤ(4). Furthermore, 
when naïve liver CD4+Tcells make contact with IL-10 producing LSECs they 
differentiate into a Treg phenotype(5). In contrast, interaction of naïve CD8+T-cells 
with LSECs results in partial T-cell activation and apoptosis, the reason for which is 
unknown(1, 2).  
 The proportion of CD8+ T-cells generally outnumbers CD4+T-cells in the liver 
although these populations fluctuate under inflammatory conditions(4, 7). For 
example, human liver biopsies show a higher number of activated CD4+T-cells in the 
presence of hepatitis, relative to the number of CD8+ T-cells(7). Most intrahepatic 
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CD4+ and CD8+ T-cells have an activated phenotype and circulate around the 
sinusoids until they encounter antigens presented by kupffer cells, immature dendritic 
cells, LSECs and hepatocytes(1, 2). In some cases, naïve T-cells interact directly 
with hepatocytes(1). Following antigen recognition these T-cells either activate, 
undergo apoptosis or differentiate into a regulatory/suppressive phenotype(1).  
1.3.  The role of cytokines in the liver and liver disease 
 
Although the liver is enriched with cytokine-rich blood from the spleen, constitutive 
cytokine production in the liver itself is absent or low(2, 8, 9). Increased cytokine 
production within the liver can lead to hepatic inflammation, apoptosis of liver cells, 
choleostasis and fibrosis(8).  
 
Unique repertoires of lymphocytes modify the immune response in the liver(2). 
However non-immune cells such as stellate cells, biliary epithelial cells, hepatocytes 
and endothelial cells are also able to produce and respond to cytokines within the 
liver, therefore contributing to local immunological potential(2, 8, 10). Infectious and 
non-infectious agents trigger the production of these cytokines, and collectively the 
roles of the lymphocytes and liver cells determine the outcome of immunological 
stimulation in the liver(2, 8). 
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1.3.1. Pro-inflammatory Cytokines  
1.3.1.1. Tumor Necrosis Factor-α 
 
Tumour Necrosis Factor-α (TNFα) is an inflammatory cytokine involved in chronic 
liver diseases and acute liver damage(10, 11). Previous data on patients with chronic 
liver disease show elevated levels of IL-6, IFNɤ and TNFα, irrespective of the 
aetiology of liver disease(8).  
 TNFα has been identified as a central mediator for apoptosis and necrotic damage in 
acute liver failure models, where infiltration of neutrophils and T-cells also occurs(8, 
11). Its levels are raised in fatty liver disease, alcohol-induced liver injury, hepatitis 
and autoimmune liver diseases(8). These diseases lead to cirrhosis of the liver, 
fibrosis and angiogenesis(2, 8).    
When the liver is exposed to inflammatory mediators such as LPS, kupffer cells 
respond by producing inflammatory cytokines such as TNFα and IFN-α, causing 
hepatocyte damage and liver injury(8, 11). Furthermore, when TLR4 on hepatocytes 
ligates to LPS, it causes the production of these pro-inflammatory cytokines such as 
TNFα, IL-6 and IL-12, which also causes hepatocyte damage(8, 10).  
1.3.1.2. Interleukin-6 
 
Interleukin-6 (IL-6) is produced by macrophages, T-cells and endothelial cells either 
constitutively or via induction of cytokines such as IL-1 or TNF(8, 12). The IL-6R has 
been identified on hepatocytes(13). In the liver, IL-6 induces cell growth and T-cell 
differentiation(8, 13). IL-6 is also secreted by kupffer cells causing hepatocytes to 
release acute-phase proteins, thus proving its ability to control local and systemic 
inflammatory reactions(12, 13). Its production increases in liver cirrhosis and has 
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been linked to non-alcoholic fatty liver disease, making it important in the co-
ordination of the inflammatory responses in the liver(2, 8).  
 
Some data suggests that IL-6 has an important role in liver regeneration and 
protection against liver disease(13, 14). One experiment demonstrated that treatment 
of IL-6 deficient mice with a single dose of IL-6 prevented liver damage(8). 
Interestingly, TNFα has also proven to be essential in hepatic regeneration. Liver 
regeneration is impaired when TNFα is blocked following chemical liver injury with 
TNFα antibodies and by knocking out TNFα(8). Collectively, this data highlights the 
relevance of inflammatory cytokines in liver damage, control of liver inflammatory 
reactions and in liver regeneration. 
1.3.2. Anti-inflammatory cytokines 
 
1.3.2.1. Transforming Growth Factor-β 
 
The cytokine TGF-β possesses immunosuppressive and anti-inflammatory 
properties(8). TGF-β1 is the most common isoform found in the liver and is secreted 
by immune cells such as kupffer cells, stellate cells and epithelial cells(10). Whilst 
activated kupffer cells in the liver are a major source of inflammatory cytokines, they 
have also been found to secrete IL-10 and TGF-β in the non-inflamed liver(2, 15). 
Interestingly, previous studies show that the expression of TGF-β1 is upregulated in 
experimental models of CCL4 induced hepatic fibrosis induced(10). 
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1.4. Characterising entosis 
 
The formation of cell-in-cell structures can be defined by entosis, cannibalism and 
emperipolesis(16, 17). Phagocytosis describes cells which engulf and degrade dying 
or pathogenic cells(18, 19). However, cannibalism describes the process whereby 
passive target cells are actively consumed by non-phagocytic  hosts(16). 
Emperipolesis is a general term for cell-in-cell structures(17, 20), which differs to 
phagocytosis as the target cells remain encased within a plasma membrane in the 
host cell in opposed entering endolysosomal compartments(16).  
 
 Entosis refers to the invasion of a target cell into its non-phagocytic host, where 
detachment from the extracellular matrix can promote homotypic cell-in-cell 
structures to form in normal and tumor cells(17, 20). Unlike cannibalism which has no 
preference over dead or alive cells, entosis describes a ‘live cell invasion’(21). These 
invading cells can die a ‘non-apoptotic cell death’ once inside the target cell(16-18). 
Alternatively these cells remain viable where they can divide, express movements, or 
exit the cell(16, 22, 23). The possible results of entosis are illustrated by Figure 3.  
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Figure 3 – A model of internalisation via entosis. A target cell (usually matrix 
detached) invades a neighbouring host cell by a Rho-dependant active 
mechanism. This target cell is then internalised where it can die by a non-
apoptotic mechanism, survive and divide, or exit the host cell(16). 
 
 
 
There are numerous examples of homotypic and heterotypic interactions resulting in 
cell-in-cell structures. Highly metastatic tumors experience cannibalism, a homotypic 
interaction which results in one tumor cell engulfing another when nutrient supplies 
are low(21, 24).  
 
Heterotypic interactions are more common. Previous studies show that tumor cells 
can engulf neutrophils and lymphocytes via cannibalism for immune evasion and 
survival(20, 21). One study found that live NK cells could internalise into 
neighbouring tumour cells via an active process similar to entosis which involved 
actin polymerisation(21). Furthermore, lymphocytes have also proven to be 
internalised by non-tumorigenic cells such as intestinal epithelial cells(16, 21).  
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Viable cells can internalise into host cells for protection. For example, 
oligodendrocytes have been observed in astrocytes within the brains of patients with 
MS(16). It was hypothesised that the internalised oligodendrocytes are shielded 
within the astrocytes to protect them from engulfment of macrophages(16). 
Occasionally, target and host cells both play a role in the formation of cell-in-cell 
structures. For example, thymocytes invade thymic nurse cells (specialised epithelial 
cells in the thymic cortex) via uropods, and likewise thymic nurse cells recruit actin to 
sites of thymocyte entry(16). 
 
A previous study highlighted the importance of receptors in the formation of cell-in-
cell structures. Human liver cells internalise Fc receptor positive NK cells via 
emperipolesis in vitro(25). Pre-incubation of liver host cells with IgG antibody (which 
binds to Fc receptors) increased internalisation of these NK cells, highlighting the 
importance of target-host cell interaction in emperipolesis(16, 25, 26). 
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1.5. CD4+ T-cells and entosis in the liver  
 
Previous work found that autoreactive CD8+T-cells invaded hepatocytes via 
emperipolesis where they were activated and degraded in endolysosomal 
compartments(27). This process of maintaining tolerance has been termed as 
“suicidal emperipolesis”(27). Furthermore, another study showed that NK cells had 
the ability to internalise in human liver cells in vitro(25). These findings have led to 
the McKeating lab at The University of Birmingham investigating emperipolesis of 
CD4+T-cells in the liver.  
 
Preliminary data demonstrated that activated CD4+Tcells invade primary hepatocytes 
where they remain viable for >16 hours (see Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mito
track
er 
Violet T-cells CMFDA Hepatocytes 
Cellmask Membrane 
Figure  4 – a. Demonstration of violet T-cells being internalise into 
green hepatocytes. b. Confocal images of CD4+T-cells being 
internalised into primary hepatocytes as well as HepG2-CD81 and 
Huh-7 hepatocellular carcinoma cell lines. The primary liver cells and 
hepatomas are stained green and CD4+Tcells are stained red. 
 
4a 
b 
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Christine Marshallsay (BMedSci Student) constructed a protocol to demonstrate the 
effects of various stimuli and their doses on the numbers of CD4+T-cells released 
from Huh-7 cells. This T-cell release assay is illustrated by Figure 5 below and the 
preliminary data is demonstrated in Figure 6.  
 
 
 
Figure 5 – (Adapted from Christine Marshallsay). This assay lasted 7 days. 
CD4+T-cells were negatively selected from human peripheral blood and 
activated with anti-CD3.28 before being incubated in IL-2 containing medium 
for 4 days. On Day 5 hepatomas and T-cells were stained and co-cultured for 24 
hours. Day 6 involved addition of masking antibody to mark T-cells which had 
not been internalised into the hepatomas. A stimulus was added to the co-
cultures which were harvested the next day. Flow analysis permitted 
quantification of non-masked, released CD4+T-cells from hepatomas. 
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Figure 6 – Preliminary data demonstrating the percentage release of violet 
CD4+T-cells from Huh-7 hepatoma lines in response to different doses of pro- 
and anti-inflammatory cytokines. The masking antibody used is anti-CD3 APC. 
The numerical value on the dot plots demonstrates the % of CD4+T-cells 
released from hepatomas. The released T-cells are expressed as a percentage 
of the total T-cell population. For detailed protocol of release assay see section 
2.1. 
 
Figure 6 suggests that pro and anti-inflammatory cytokines may have an effect on the 
percentage of CD4+T-cells released from Huh-7 hepatomas.  
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1.6. Aims & Objectives 
 
The aim is to mimic specific conditions present in the liver in vitro to investigate which 
environment causes the release of CD4+T-cells from hepatocytes following entosis. 
First the release assay protocol originally designed by Christine Marshallsay will be 
optimised. This protocol will involve co-culture of T-cells with Huh-7 and HepG2-
CD81 hepatoma cell lines to encourage spontaneous entosis, and quantification of T-
cell release using flow cytometry. The percentage of T-cell release from the co-
culture will be measured in response to stimuli, dose responses and incubation times. 
We hypothesise that pro-inflammatory cytokines such as TNFα, IFNɤ and IL-6 will 
reduce T-cell release following entosis. This would explain a tolerogenic mechanism 
in the liver for CD4+ T-cells, to prevent further inflammation in the liver.  
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2. Materials & Methods 
2.1. The T-cell release assay  
 
This study was based on a 7-day release assay. On Day 1 CD4+T-cells were isolated 
via negative selection from human peripheral blood as described in 2.5, and 
incubated for 4 days in IL-2 containing media. All these T-cells were CD3+ ve. By 
incubating these T-cells with hepatomas for 24 hours on Day 5, a proportion of these 
cells were internalised. Anti-CD3-APC was added to the coculture on Day 6 for 30 
minutes and washed off. This antibody reached all the exposed T-cells which were 
outside hepatomas, but did not reach internalised T-cells. This allowed use of anti-
CD3 as a “masking” antibody to label all non-internalised T-cells.  The co-culture was 
harvested after 24 hours on Day 7 and anti-CD3-APC fluorescence was analysed by 
flow cytometry. This permitted separation of the T-cells into CD3+ and CD3-ve 
populations. The CD3-ve population represented T-cells which were released from 
the hepatomas after addition of the masking antibody. To confirm that the masking 
antibody had labelled most T-cells efficiently, some cells were harvested and fixed 
immediately after the masking antibody had been washed off at Day 6. Co-cultures 
were harvested at Day 7 to quantify the increased proportion of masking antibody -ve 
T-cells. These represented T-cells released spontaneously in medium only, without 
addition of pro-inflammatory stimuli. To assess any potential effects of inflammatory 
mediators, we compare the release of T-cells in medium only to T-cells released in 
the presence of stimuli which were added to the co-culture immediately after removal 
of masking antibody on Day 6.  
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Each condition was performed with 2 or 3 replicates (see Figure 7). T-cells and 
hepatomas were easy to discriminate from each other using forward and side scatter 
measurements. To aid this distinction further, T-cells and hepatomas were pre-
labelled with CellTracker dyes in violet and green respectively. To monitor T-cell cell 
divisions, we used CellTrace violet, which reduces in fluorescence intensity when 
cells divide. 
 
 
 
Figure 7 – An example of an experimental setup including treatments (TNFα +/- 
inhibitor) and controls on a 24-well plate. The number of wells that were treated 
depended on the experiment. The controls in the final column were repeated in 
all release assays 
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2.2. The biotin assay 
 
This assay was performed over 7 days and acted as a quality control assay to 
support optimisation of the release assay protocol. Biotin labels the primary amines 
expressed on the surface of T-cells. CD4+T-cells were isolated from human blood 
(Day 1) and cultured in IL-2 containing media for 4 days. On day 5 T-cells were 
stained violet and biotinylated according to 2.9, before being co-cultured with the 
green hepatocytes for 24 hours. This allowed the biotinylated T-cells to internalise 
into the hepatomas. On Day 6, biotinylated T-cells which were not internalised into 
HepG2-CD81 cells were then masked with Streptavidin-PE antibody which binds with 
high affinity to biotin. Excess antibody was washed away after 30 minutes and 
desired treatments were incubated with the co-culture for 24 hours. On Day 7, 
streptavidin-APC780, which also binds with high affinity to biotin, was added for 30 
minutes prior to harvesting. This masked all internalised and non-internalised 
biotinylated T-cells, and formed a control to confirm efficient biotinylation of all the T-
cells. The co-culture was harvested and the percentages of strep-PE negative, strep-
APC positive T-cells were then measured via flow cytometry. These T-cells 
represented the ‘released’ population of T-cells from the hepatomas. This assay is 
demonstrated by Figure 8. 
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Figure 8 – The biotin release assay as described in 2.2, was used to optimise 
the original T-cell release assay described in 2.1. by Figure 5. Controls were 
strep-PE cultured with non-biotinylated T-cells, strep-APC780 cultured with 
non-biotinylated T-cells, strep-PE cultured with biotinylated T-cells, strep-
APC780 cultured with biotinylated T-cells and strep-PE and APC780 cultured 
with biotinylated T-cells. The ‘at masking’ (Day 6) and ‘after masking’ (Day 7) 
controls were repeated from release assays (2.1.) using strep-PE to exposed 
mask biotinylated T-cells from the HepG2-CD81-T-cell co-culture. 
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2.3. HepG2-CD81 hepatocyte cell line 
The HepG2 line has lost CD81 expression. However, in this study HepG2 cells were 
transduced with CD81 under antibiotic selection in order to mimic hepatocytes in 
vivo. 
Cells were cultured in  DMEM (Deilbecco’s modified eagle medium) supplemented 
with 10% Foetal Bovine Serum (FBS), 1% Streptomycin, 1% L-glutamine and 1% 
non-essential amino acids to form a 10%DMEM, (Gibco, Life Technologies, UK) and 
Zeocin used at 1mg/ml (Invitrogen, Life Technologies, UK) to select for CD81+ cells. 
The cells were stored in an incubator at 37°C in 5% CO2 and split every three days to 
prevent overgrowth and death. 
 
2.4. Seeding HepG2-CD81 cells 
The HepG2-CD81 cells were washed and incubated with 0.25% trypsin-EDTA 
solution (Gibco, Life Technologies, UK) for 4 minutes to dislodge the cells from the 
flask. The cells were lifted and the trypsin was inactivated with 10%DMEM. The cell 
mixture was brought to a volume of 26ml with zeocin containing media. 1ml of the cell 
suspension was then pipetted into each well of the 24-well plates, before being 
incubated for 3 days to allow T-cell populations to expand. 
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2.5. Isolating CD4+ T-lymphocytes 
 
Blood was provided by hematomacrosis patients at the Queen Elizabeth Hospital, 
Birmingham. Samples were spun for 20 minutes at 2000RPM to fractionate the 
blood. The leucocyte buffy coat was harvested and pooled before being diluted with 
sterile PBS (Gibco, Life Technologies, UK). Diluted leucocytes were layered over 
Lympholyte®-H (Cedarlane Labs, Canada) and spun again at 2000RPM without 
brake for 30 minutes. The lymphocyte layer was later removed and re-suspended in 
RPMI Medium-1640(L-Glu) containing 10% FBS, 1% Streptomycin and 1% non-
essential amino acids (Gibco, Life Technologies, UK).  The lymphocytes were 
centrifuged again for 5 minutes at 1500RPM before being washed with RPMI and 
counted.  
 
CD4+T-cells were negatively selected using an EasySep Human CD4+ T-cell 
Enrichment Kit (Stemcell Technologies, UK) according to manufacturer’s instructions. 
Lymphocytes were re-suspended at a concentration of 5x107 cells/ml in RPMI. The 
EasySep Human CD4+ T-cell enrichment cocktail was added to the cell suspension 
at 50µl/ml and incubated at room temperature for 10 minutes. Following incubation, 
the EasySep magnetic particles were added to the cell suspension at 100µl/ml and 
incubated again for 5 minutes at room temperature. The cell suspension was then 
brought to a specific volume using RPMI (depending on the PBMC number), before 
being placed into the EasySep magnet for 5 minutes. Unattached CD4+T-cells were 
removed and activated with anti-CD3.28 human mAb at 1µg/ml (eBioscience, UK) 
before being incubated for 20 minutes at 37°C. Following activation, IL-2 was added 
to the T-cells at 500IU (PeproTech, UK) and ~2 million T-cells were seeded in a 24-
well plate. 
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2.6. Preparing the co-culture 
2.6.1. Staining HepG2-CD81 cells 
 
CellTracker green (CMFDA) (Life Technologies, Invitrogen, UK) was diluted with 
Serum Free Medium (SFM) (RPMI1640 L-glutamine, 1% Streptomycin and 1% non-
essential amino acids) (Gibco, Life Technologies, UK) to form a working 
concentration 0.02mM. 250µl of the diluted CMFDA was then added to each well of 
the 24-well plate and incubated at 37ºC for 40 minutes. Following incubation, wells 
were washed with 10% DMEM, and then incubated with 250µl of 10% DMEM until 
the T-cells were prepared for co-culture.  
 
2.6.2. Staining purified T-lymphocytes 
 
2.6.2.1. Cell Tracker Violet 
 
Initially, T-cells were stained with CellTracker Violet (Life Technologies, Invitrogen, 
UK) which was diluted with SFM to form a working concentration of 0.02mM. 
Meanwhile, the T-cell suspension was centrifuged at 20°C for 3 minutes at 
1500RPM. The violet-dye solution was used to re-suspend the T-cell pellet, before 
being incubated at 37°C for 30 minutes. Following incubation the violet T-cells were 
centrifuged again and re-suspended in 10%DMEM. 50µl containing 0.5x106 violet T-
cells were then co-cultured and incubated with CMFDA-labelled HepG2-CD81 cells 
for 24 hours. 
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2.6.2.2. Violet cell Trace 
 
Following the first experiment, a CellTrace Violet Proliferation Kit (Life Technologies, 
Invitrogen, UK) was used to dye T-cells. 
CellTrace Violet was diluted with SFM to form a working concentration of 5µM, which 
was mixed with the T-cells and incubated for 20 minutes at 37°C. The cells were 
centrifuged, re-suspended in 1ml of 10%DMEM and incubated for 10 minutes. The 
cell suspension was centrifuged again and the T-cell pellet was re-suspended in 
10%DMEM. As previously, 50µl containing 0.5x106 violet T-cells were added to each 
well of CMFDA-labelled HepG2-CD81 cells and incubated for 24 hours. 
2.7.  Co-culture Treatment 
2.7.1. Masking antibody addition 
 
Mouse anti-human CD4-APC (BD Pharmingen, BD Biosciences, UK) was used as 
masking antibody to stain non-internalised CD4+Tcells. This masking Antibody was 
administered to the co-culture for 30 minutes, and excess antibody was washed 
away. After masking the treatment solutions were also administered to the wells. 
 In one experiment, a panel of anti-human antibodies were tested for their masking 
efficiency: CD2-APC, CD3-APC, CD5-APC (BD Pharmingen, BD Biosciences, UK), 
CD43-FITC and CD45-FITC (Biolegend, UK). All antibodies were used at a 1:100 
dilution.  
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2.7.2. Treatment addition 
 
250µl of 10%DMEM containing each treatment was added to each well and left to 
incubate with the co-culture for 24 hours. Figure 7 demonstrates an example of a 
plate used to test the T-cell release response to different concentrations of TNFα 
(PeproTech, UK) in the presence and absence of anti-human TNFα mAb 
(PeproTech, UK). In the case of the other cytokines and growth factor treatments 
(PeproTech, UK), varying concentrations were used (see results).  
2.8.  Fixing cells 
 
On Day 7, co-cultures were harvested into FACSs tubes using 2mM EDTA 
(ethylenediaminetetraacetic acid) (Sigma-Aldrich, UK). All samples were fixed for 5 
minutes with 4% paraformaldehyde (PFA) (Sigma-Aldrich, UK) and were filtered prior 
to flow analysis.  
 
2.9. Biotinylation and streptavidin masking of CD4+ T-cells 
  
Sulfo-NHS-LC-Biotin (Thermo Scientific, UK) was re-suspended in sterile PBS to 
form a 2mM solution. The T-cell suspension was then washed with sterile PBS to 
remove amine-containing media from the cells, before being re-suspended in the 
biotin solution and incubated at room temperature for 30 minutes. The biotinylated T-
cells were washed again with PBS and 100mM of glycine to quench excess biotin 
reagents, before being re-suspended in 10%DMEM. These T-cells were then added 
to the co-culture for 24 hours, after which streptavidin-PE (affymetrix, eBioscience, 
UK) was added as the masking antibody (1µg/ml). 24 hours after masking, 
streptavidin-APC780 (affymetrix, eBioscience, UK) was also added to the treated co-
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culture for 30 minutes (at 1µg/ml). The co-culture was then harvested according to 
2.8. prior to flow analysis.  
 
2.10. Using the Huh-7 cell line 
 
Huh-7 hepatomas were used to increase the number of T-cell internalisation events. 
The same experimental procedure was used as with the HepG2-CD81 and violet T-
cell co-culture, however mouse anti-human CD5 PE-CY7 (BD Pharmingen, BD 
Biosciences, UK) was used as the masking antibody at a 1:100 dilution. Due to their 
rapid growth, the Huh-7 cells were seeded on a 24 well plate and co-cultured 3 hours 
later with violet T-cells. 
2.11. Controls 
 
The following controls were used in the T-cell release assay: unstained HepG2-
CD81s containing no T-cells/treatments, CMFDA green stained HepG2-CD81s with 
no T-cells/treatments, 0.5x106 unstained T-cells, 0.5x106 violet T-cells, untreated 
green HepG2-CD81 and violet T-cell co-cultures at masking (fixed at Day 6), and an 
untreated well with green HepG2-CD81 and violet T-cell co-cultures after masking 
(fixed at Day 7). Figure 7 demonstrates the experimental set-up of one plate. See 
Figure 5 and section 2.1.for detailed assay protocol.  
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3. Results 
 
The aim of this study was to optimise a method to accurately measure the 
percentage release of CD4+T-cells from hepatoma cell lines. Once optimised, the aim 
was to detect the effect of various stimuli on CD4+T-cell release from hepatomas. 
Data measuring the percentage of released unmasked CD4+T-cells was then 
collected using a DAKO cyan flow cytometer and analysed using FlowJo. 
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3.1. Gating on released CD4+T-cells 
 
Flow cytometry was used to quantify CD4+T-cell and hepatoma events. A gate was 
placed around the T-cell population and ~20,000 T-cell events were collected (Figure 
9). When analysing raw data using FlowJo, the T-cell events were backgated to 
ensure that no hepatoma cells fell into the T-cell gate to affect the results. 
 
Figure 9 – Example of control results from Day 6 (At masking) collected by flow 
cytometry. The orange gate represents the HepG2-CD81 cells and the red gate 
represents violet CD4+Tcells. These results were backgated to ensure that 
there was no overlap between the two cell types. The flow diagram on the right 
shows the % of T-cells released. Released T-cells that were not accessible to 
the masking antibody are anti-CD4-APC negative. The released T-cells are 
expressed as a percentage of the total T-cell population gated on the left (red).  
 
  
 
36 
 
The gate around the cells negative for ‘Anti-CD4 APC’ and positive for ‘Violet CD4+T-
cells’ represent the percentage of T-cells  released from HepG2-CD81 cells. The 
population positive for ‘Anti-CD4 APC’ and ‘Violet CD4+T-cells’ represents non-
internalised, anti-CD4 masked T-cells outside the HepG2-CD81 cells. Those negative 
for both anti-CD4 and Violet T-cells represent unstained T-cells, dead cells and 
debris. 
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3.2. T-cell release assays 
3.2.1. The percentage release of CD4+T-cells from HepG2-CD81s 
does not increase in the presence of inflammatory 
conditions 
 
Experiment 1 and 2 was setup to compare %T-cell release when anti-CD4 APC 
masking antibody and HepG2-CD81 hepatomas were used in the release assay, in 
opposed to the anti-CD3 APC and Huh-7 hepatomas used in preliminary 
experiments. Results are displayed in Figure 10. 
  
Figure 10 – Dot plots comparing preliminary data to my Experiments 1 and 
2.The preliminary experiments used anti-CD3 mAb for masking whereas 
Experiments 1 and 2 use anti-CD4 masking antibody to measure %T-cell 
release from untreated and treated (TNFα treatment 100ng/ml) co-cultures. The 
left column demonstrates T-cell release in the untreated controls at masking 
(Day 6), whereas the second column demonstrates T-cell release in the 
untreated controls after masking (Day 7). Co-cultures were treated for 24 hours 
prior to flow analysis at Day 7. 
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Preliminary data in Figure 10 shows an increase in the percentage of CD4+T-cells 
released 24 hours after treatment compared to untreated controls. Experiments 1 and 
2 do not demonstrate a great increase in %T-cell release in the TNFα treated co-
culture compared to untreated controls; however show increased T-cell proliferation 
compared to the preliminary data. This indicates that levels of entosis and release 
may differ according to the type of hepatoma cell line used. 
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3.2.2. Percentage release of CD4+T-cells from HepG2-CD81-CD81 
cells is not dependant on the dose of TNFα 
 
This experiment measured % T-cell release in response to increasing doses to TNFα 
in the presence and absence of the TNFα inhibitor anti-TNF (Figure 11). The inhibitor 
was used to determine whether the T-cell release observed was truly induced by 
TNFα dose treatment. 
 
 
 
Figure 11 –Experiment 1: (n=2) Graphs to show the effects of different 
concentrations of TNFα treatment in the absence (left) and presence (right) of 
inhibitor (anti-TNFα), on %T-cell release from HepG2-CD81 hepatomas. The 
doses of TNFα used in the release assay presented a one log difference (100, 
10, 1, 0.01ng/ml). TNFα +/- inhibitor was incubated with theHepG2-CD81-T-cell 
co-culture for 24 hours before %T-cell released was measured on Day 7.  
Released T-cells were expressed as percentages of the total gated T-cell 
population. Error bars represent the standard error of the mean (SEM). 
Statistically significant results are presented by a * where p<0.05.  
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Figure 11 (left) shows that treatment with 1ng/ml of TNFα induces a significantly 
higher %T-cell release compared to the untreated control.  
Figure 11 (right) shows that %T-cell release in the presence of TNFα +Inhibitor is 
similar compared to the TNFα treated co-cultures. The %T-cell release was 
significantly higher where 10ng/ml of TNFα +inhibitor was used to treat the co-
culture; however the overall %T-cell release in this experiment is low.  
The results imply that T-cell release from HepG2-CD81s may not be dose 
dependant. It is also possible that the inhibitory activity in this experiment is not 
effective due to the %T-cell release being similar to treated samples without inhibitor. 
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The next release assay involved T-cells from a different donor. This experiment 
measured % T-cell release in response to increasing doses to TNFα with a two log 
difference in the presence and absence of anti-TNF (Figure 12).  
 
 
 
Figure 12- Experiment 2: (n=2)  Graphs to show the effects of different 
concentrations of TNFα treatment in the absence (left) and presence (right) of 
inhibitor (anti-TNFα), on %T-cell release from HepG2-CD81 hepatomas. TNFα 
concentrations were used with a two log difference was used (100, 1, 0.01, 
0.0001ng/ml). TNFα +/- inhibitor was incubated with the HepG2-CD81-T-cell co-
culture for 24 hours before %T-cell released was measured on Day 7. Error 
bars represent the S.E.M. Statistically significant results are presented by a * 
where p<0.05, and ** where p<0.01.  
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Figure 12 (left) shows that treatment with 1ng/ml of TNFα induced a significantly 
higher %T-cell release compared to the untreated control where p=0.003.  
In Figure 12 (Right) The Treatments of TNFα + Inhibitor show a similar %T-cell 
release compared to in the presence of TNFα alone (left). Treatment with 
0.0001ng/ml and 0.01ng/ml of TNFα +inhibitor induced a significantly higher %T-cell 
release compared to untreated controls where p=0.02 and 0.04 respectively.   
This data further indicates that T-release from HepG2-CD81s following entosis is 
probably not dose dependant. 
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3.2.3. TNFα +inhibitor (anti-TNFα) has a profound effect on the 
size and granularity of HepG2-CD81 cells   
 
To investigate effects of TNFα on hepatoma biology, we looked at forward and side 
scatter profiles of these cells before and after treatment. Figure 13 shows that in the 
presence of TNFα +inhibitor, the size and granularity of HepG2-CD81 changes, 
where the population splits into two, with the larger population shifting to the left. This 
shows that TNFα treatment had a profound effect in hepatoma morphology. No 
cytotoxicity was noted by trypan blue staining.
 
Figure 13 – Flow diagram from Experiment 1 and 2 demonstrating a change in 
HepG2-CD81 morphology in the presence of TNFα +inhibitor (anti-TNFα) 
compared to TNFα treated samples. TNFα +/- inhibitor was incubated with the 
T-cell-HepG2-CD81 co-culture on Day 6 for 24 hours. Results were collected via 
flow cytometry on Day 7.  
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3.2.4. Anti-CD5 antibody masks non-endocytosed Violet CD4+ T-
cells more efficiently compared to anti-CD4 in T-cell release 
assays 
 
As CD3 and CD4 became downregulated following stimulation of the co-cultured 
cells with TNFα, we set out to identify more antigens for use as masking reagents in 
our release assay. The optimal antigens would be present in all T-cells and would not 
be downregulated on the T-cell surface after treatment. Figure 14 demonstrates the 
masking efficiency of a panel of antibodies used in release assays. 
 
Figure 14 - Histograms demonstrating the efficiency of a panel of antibodies for 
masking CD4+T-cell in TNFα (1ng/ml) treated and untreated samples. A shift of 
histograms to the left demonstrates loss of fluorescence and inefficient masking of 
T-cells. During the released assay, exposed T-cells from the T-cell-HepG2-CD81 co-
cultures were masked with a panel of antibodies on Day 6 before treatment was 
added for 24 hours. Results were collected on Day 7 via flow cytometry.  
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Table 2 – Description of the efficiency of each of the antibodies tested as 
masking antibodies in the release assay. 
 
Figure 14 shows that anti-CD5 PE-CY7 remains bright throughout the co-culture with 
HepG2-CD81 in the presence and absence of TNFα treatment. Other antibodies 
display reduced brightness or fluorescence is lost completely following co-culture. We 
therefore established that CD5 would be the optimal antigen to target for T-cell 
masking in the release assay.  
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3.2.5. Streptavidin-PE antibody efficiently masks non-internalised 
biotinylated CD4+ T-cells  
 
To confirm that the masking antibody assay truly reveals released T-cells, we set up 
a new method to identify released T-cells in the release assay using Streptavidin-PE 
as a masking antibody (See 2.2.). The first experiment was conducted to test whether 
strep-PE and strep-APC bound efficiently to biotinylated T-cells (Figure 15). 
 
 
Figure 15 – Dot plots demonstrating the effectiveness of Streptavidin-APC and 
Streptavidin-PE binding to biotinylated CD4+T-cells alone. T-cells were stained 
violet and half were biotinylated on Day 5 before being cultured in media alone 
for 24 hours. Streptavidin-PE was added to the biotinylated and non-
biotinylated T-cells on Day 6. Streptavidin-APC780 was the control to confirm 
biotinylation of all T-cells and was added to the biotinylated and non-
biotinylated T-cells on Day 7 for 30 minutes prior to harvesting. Results were 
collected on Day 7 and analysed via flow cytometry. Strep-PE/APC +ve, violet 
biotin +ve populations represent antibody bound T-cells. 
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The top two dot plots of Figure 15 show that in the absence of biotin, Streptavidin-PE 
and Streptavidin-APC780 are not effective at binding to violet T-cells. The bottom two 
diagrams show that individually, Streptavidin-PE and APC bind effectively to 
biotinylated violet T-cells (where in both cases >90% of bionylated T-cells are bound 
by Streptavidin APC/PE). Results from this experiment show that streptavidin-PE 
may be an effective masking antibody of biotinylated T-cells. 
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The aim of the next experiment was to test if strep-PE and strep-APC780 could 
simultaneously bind to the majority of the biotinylated T-cell population (Figure 16). 
 
 
                                   
 
 
 
 
 
 
 
 
Figure 16 – Diagram demonstrating the effectiveness of both Strep-PE and 
Strep-APC at binding to biotinylated violet CD4+Tcells. A population of the T-
cells were biotinylated on Day 5 and cultured alone for 24 hours. On Day 6 
streptavidin-PE was added to biotinylated T-cells for 30 minutes. On Day 7 
strep-APC780 was also added to the biotinylated T-cells for 30 minutes after 
which the double-masked T-cells were harvested and analysed via flow 
cytometry. Strep-PE +ve, strep-APC +ve T-cells represent the double masked T-
cells population. 
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Figure 16 shows that in the presence of both Streptavidin-APC and Streptavidin-PE, 
(the double positive population) >85% of biotinylated violet T-cell population is 
masked. These results show that streptavidin-PE would be effective as a masking 
antibody of biotinylated T-cells and streptavidin-APC780 would effective as a control 
marker to confirm T-cell biotinylation in release assays. 
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3.2.6. Anti-CD5 antibody efficiently masks non-internalised 
CD4+Tcells 
 
The next experiment used streptavidin-PE in parallel to anti-CD5 PE-CY7 to confirm 
the efficiency of anti-CD5 PE-CY7 as a masking antibody in release assays (Figure 
17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 – Dot plots comparing %T-cell release from HepG2-CD81s in treated 
and untreated co-cultures, using anti-CD5 PE-CY7 and streptavidin-PE as 
masking antibodies. Values underlined in red demonstrate the percentage of 
violet CD4+T-cells released from HepG2-CD81s. T-cells were stained violet and 
half were biotinylated prior to co-culture on Day 5. The streptavidin-PE was 
then added as the masking antibody in co-cultures containing biotinylated T-
cells on Day 6. Streptavidin-APC780 acted as the control to prove complete T-
cell biotinylation, and was added to the co-culture on Day 7 for 30 minutes 
prior to harvesting.  Anti-CD5 was used to mask un-biotinylated violet T-cells 
from the release assay as Figure 6 states. Results were collected on Day 7 via 
flow cytometry. Violet +ve, CD5 –ve populations represent released T-cells in 
anti-CD5 masked assays. Strep-APC +ve, strep-PE –ve populations represent 
released T-cells in strep-PE masked assays. 
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Figure 17 shows that where anti-CD5 is used as a masking antibody, the %T-cell 
release is similar in treated and untreated co-cultures. This result is repeated where 
streptavidin-PE is used as a masking antibody, as the %T-cell release is similar 
between treated and untreated co-cultures.  
The similar T-cell release measured by both strep-PE and anti-CD5 PE-CY7, 
provides confirmation that anti-CD5 is a suitable to use as a masking antibody during 
subsequent release assays.  
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3.2.7. Percentage release of violet CD4+T-cells from Huh-7s is not 
stimuli dependant 
 
After optimising the release protocol, the effects of stimuli on T-cell release was 
investigated in another hepatoma cell line. Huh-7 cells from a confluent monolayer 
and are different from HepG2-CD81 cells because they do not polarise in culture. 
The effects of pro-inflammatory, anti-inflammatory and hypoxia treatment on the 
percentage T-cell release from Huh-7s were tested (Figure 18 and 19).   
 
Figure 18 – Dot plots to demonstrate the % release of violet T-cells from Huh-7s 
3 hours following incubation with treatments (in opposed to 24 hours). Here the 
T-cells were masked with anti-CD5 PE-CY7, treated and harvested on Day 6. 
Here anti-inflammatory (TGF), pro-inflammatory (IL-6) and hypoxic conditions 
(CoCl2) were tested. The anti-CD5 negative, violet positive population 
represents %released T-cells underlined in red.  
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Figure 18 shows that the percentages of released T-cells are similar both between 
the treatments and in comparison to the control. This implies that the release of 
CD4+T-cells from Huh-7s is not stimuli dependant. 
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Figure 19 - Bar graph (n=2) Demonstrating the effects of 3 hour treatments on 
percentage T-cell release from Huh-7s.Co-cultures were masked with anti-CD5 
and treatments were incubated with co-cultures for 3 hours before harvesting 
and flow analysis (All on Day 6). Here anti-inflammatory (TGFβ), pro-
inflammatory (IL-6, TNFα, IFNɤ, IL-2), growth factors (VEGF) and hypoxic 
conditions (CoCl2) were added as treatments in release assays. Bars represent 
S.E.M. Results which are significantly lower compared to the untreated co-
culture are presented by a * where p<0.05. To calculate statistical significant 
data a paired T-test was performed. 
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Figure 19 shows that pro and anti-inflammatory cytokines, growth factors and hypoxic 
conditions mostly induce a similar %T-cell release from 3 hour Huh-7 co-cultures. 
However, the % T-cell release is significantly lower with IFNɤ treatment compared to 
that of untreated controls. Collectively this data implies that IFNɤ may have an effect 
on %T-cell release from Huh-7s. 
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3.2.8. 2 hour incubations with treatments results in significantly 
increased %T-cell release from HepG2-CD81s compared to 
24 hour incubations  
 
To determine whether treatment incubation times influenced %T-cell release in 
release assays, an experiment was conducted using 2 and 24 hour incubations in the 
presence of IFNɤ (Figure 20).  
 
 
Figure 20 – Dot plots demonstrating the effects of incubation time and cytokine 
treatment (IFNɣ 100ng/ml) on T-cell release from HepG2-CD81 hepatomas. The 
anti-CD5 PE-CY7 negative, violet positive populations represent the % of 
released T-cells, where the values are underlined in red. Here the non-
internalised T-cells were masked with anti-CD5 before being treated with IFNɣ 
on Day 6. Co-cultures were harvested for flow analysis at 2 hours and 24 hours 
(Day 6 and 7 respectively). 
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Figure 20 shows that the %T-cell release is greater in treated and untreated co-
cultures at 2 hours compared to 24 hours. The results show that IFNɣ treatment 
induced lower %T-cell release from HepG2-CD81s at 2 hours compared to untreated 
controls. This reinforces the possibility that IFNɤ may be involved in preventing T-cell 
release following entosis.  
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An experiment was performed to determine whether incubation times (2h and 24h) in 
the presence of other stimuli influenced %T-cell release in release assays (Figure 
21). 
 
 
Figure 21– Bar graph (n=2) demonstrating the effects of 2 hour and 24 hour 
treatment incubation times on percentage T-cell release from HepG2-CD81 
cells. Non-internalised T-cells were masked with anti-CD5 before being treated 
with various stimuli and harvested for flow analysis at 2 hours and 24 hours 
(Day 6 and 7) respectively. Here pro-inflammatory (TNFα, IFNɤ) and anti-
inflammatory cytokines (TGFβ) were used as treatments. Error bars represent 
the S.E.M. Statistically significant results are presented by a * where p<0.05. To 
calculate statistical significances within the data a paired T-test was 
performed. 
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Figure 21 demonstrates that the percentage release of T-cells is significantly greater 
at 2 hours compared to 24 hours in the untreated and treated co-cultures.  
These results indicate that T-cell release is time dependant rather than stimuli 
dependant.  
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3.2.9. There is no significant change in %T-cell release from Huh-
7 cells with 2 hour treatment incubations compared to 24 
hour treatment incubations  
 
The same experiment was repeated to assess whether 2 hour and 24 hour 
incubations had an effect on release assays involving Huh-7s. It is also possible that 
T-cell release from hepatomas is induced by a combination of treatments in opposed 
to a single stimulus. Therefore some treatments in this experiment were used in 
combination to test their effects on %T-cell release (Figure 22).  
 
Figure 22 - Bar graph (n=2)  demonstrating the effects of 2 hour and 24 hour 
treatment incubation times on percentage T-cell release from Huh-7 cells. Non-
internalised T-cells were masked with anti-CD5 on Day 6 before being treated 
with various stimuli and harvested for flow analysis at 2 hours and 24 hours 
(Day 6 and 7) respectively. Here pro-inflammatory cytokines were used in 
combination (TNFα, IFNɤ and IL-2,IL-6). Anti-inflammatory cytokines (TGFβ) 
and growth factors (VEGF) were also used as treatments. Error bars represent 
the S.E.M.  
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Figure 22 shows that none of the treated co-cultures show a significantly different 
%T-cell release compared to untreated co-cultures. There is also no significant 
difference in %T-cell release between 2-hour and 24-hour treated co-cultures.  
This shows that the higher T-cell released observed at 2 hours in the previous 
experiment may be HepG2-CD81 specific.  
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3.3. Lymphocyte-hepatocyte interactions 
3.3.1. Co-culture of hepatocytes with T-cells causes 
downregulation of CD2 on CD4+T-cells 
 
When screening for optimal masking antigens for our release assay, we discovered 
that CD2 becomes downregulated upon co-culture with hepatomas. To investigate 
this further we did a time course experiment in the presence or absence of IL-2 and 
IL-6. These cytokines were used to mimic a liver inflammatory response in vitro(8).
 
 
Figure 22- Dot plots demonstrating violet T-cell release from Huh-7 cells, 2 and 
24 hours following incubation with IL-2 and IL-6. Both anti-CD2 APC and anti-
CD5 PE-CY7 are used as masking antibodies at Day 6 and released T-cells are 
demonstrated as negative for both anti-CD2 and anti-CD5 (values underlined in 
red). Co-cultures were then harvested for flow analysis on Day 6 and 7 after 2 
and 24 hour treatments respectively. 
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Figure 22 shows that in the presence of co-culture with Huh-7 hepatomas, CD2 on T-
cells is down-regulated, which is demonstrated by the shift in T-cell population to the 
left in the untreated samples at 24 hours. This downregulation of CD2 on T-cells 
increases in the presence of the pro-inflammatory cytokines IL-6 and IL-2, 24 hours 
following stimulation.  
This shows that the pro-inflammatory cytokines IL-2 and IL-6 may influence CD2 
surface expression on CD4+T-cells. 
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4. Discussion 
 
From these experiments, a well-defined release assay has been established to 
accurately measure T-cell release from HepG2-CD81s and Huh-7 cell lines. 
However, there is no strong evidence to suggest that pro-inflammatory cytokines 
(TNFα, IL-6, IL-2, IFNɤ), anti-inflammatory cytokines (TGF-β), growth factors (VEGF) 
or hypoxic conditions (CoCl2) significantly increase or reduce the release of T-cells 
from hepatomas following entosis. 
 The HepG2-CD81 hepatocellular carcinoma cell line used in parts of this study 
presents epithelial cell morphology. They were used in this in vitro study due to their 
ability to polarise and form apical and basolateral surface domains, which resemble 
the bile canalicular and sinusoidal domains observed in vivo within polarized human 
hepatocytes.  
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4.1. The effects of TNFα on T-cell release from HepG2-CD81 
hepatomas 
 
TNF-α was used to treat the T-cell-HepG2-CD81 co-culture, in order to mimic pro-
inflammatory conditions in the liver. 
Preliminary data (Figure 10) showed that TNFα treatment may be promoting T-cell 
release following entosis using an assay based on identifying released cells by lack 
of anti-CD3 antibody access (see section 2.1.). A potential interpretation for the 
increase in the CD3 –ve population in the cytokine treated co-culture is the 
downregulation of CD3 by the T-cells. To investigate this, I used anti-CD4 in this 
assay and found that CD4 indeed becomes downregulated, but not completely 
undetectable from the T-cell surface by flow cytometry like CD3. This ‘loss’ of anti-
CD3 mAb makes it difficult to distinguish between released and non-released T-cell 
populations, therefore affecting accurate positioning of the ‘released T-cell gate’. This 
partly eliminated the previous problem, however showed that there was now no 
significant increase in T-cell release from HepG2-CD81s following treatment with 
TNFα (100ng/ml), but increased T-cell proliferation. To rule out the effect of TNFα on 
T-cell proliferation, cells were labelled with CellTrace violet. This reagent confers 
violet fluorescence that reduces by half after each cell division. This way we could 
monitor if a treatment truly increases T-cell release or causes existing T-cell 
proliferation.  
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4.2. The effects of TNFα doses +/- inhibitor on T-cell release 
from HepG2-CD81 hepatomas 
 
Results from Figures 11 and 12 implied that %T-cell release is not dependant on the 
dosage of TNFα as there is no correlation between TNFα dosages and T-cell 
release.  
Previous work demonstrated that under certain circumstances, hepatocytes are able 
to produce TNFα(9).The absence of correlation between TNFα doses and T-cell 
release could be because the hepatomas themselves are producing TNFα, therefore 
inducing large amounts of T-cell release and eliminating the effects of TNFα dose 
responses on T-cell release. This may explain why the overall %T-cell release in the 
treated and control groups are low (Figures 11 and 12).  
The overall %T-cell release was similar in the TNFα treated groups compared to 
those with TNFα +inhibitor, suggesting that the inhibitor was ineffective at blocking 
TNF-induced release. If the hepatomas themselves are producing TNFα, it may be 
that that the concentration of inhibitor was not high enough to saturate the amount of 
TNFα present.  
Further results show that TNFα +inhibitor affected the granularity and morphology of 
the HepG2-CD81s (Figure 13). This may be because in the presence of TNFα alone 
the HepG2-CD81s become depolarised and therefore have a different shape and 
size compared to in the presence of the inhibitor, where the majority of TNFα is 
blocked. 
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4.3. Establishing a masking antibody for non-internalised 
violet T-cells 
 
The downregulation of CD3 and CD4 described in 4.1, led to an investigation to find 
a suitable masking antibody that would target an antigen on T-cells which was not 
downregulated. Anti-CD5 PE-CY7 was identified as the most suitable masking 
antibody from an antibody panel which were tested in release assays (Figure 14). 
This is because this anti-CD5 did not lose fluorescence during co-culture and CD5 
was not downregulated on T-cells throughout the assay. 
As the efficiency of streptavidin-PE was already confirmed as a masking antibody for 
biotinylated T-cells (Figure 15 and 16), this protocol was used in parallel to anti-CD5, 
to confirm its masking efficiency. Figure 17 demonstrates that anti-CD5 PE-Cy7 is 
efficient at masking CD4+T-cells as the percentage release of T-cells from HepG2-
CD81s in these experiments match those where Strep-PE is used for masking. As a 
result the following experiments used anti-CD5 PE-CY7 as a masking antibody for 
non-internalised T-cells. 
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4.4. The effects of time on T-cell release from HepG2-CD81 
and Huh-7 hepatomas 
 
Results show that T-cell release was significantly greater at 2 hours compared to 24 
hours in untreated and treated co-cultures involving HepG2-CD81 hepatomas (Figure 
21). When the assay was repeated in Huh-7s, no significant differences were found. 
It is possible that entosis and T-cell release occurs in a continuous cycle. This cycle 
may occur at a slower rate in HepG2-CD81 co-cultures due to the HepG2 polarised 
cluster morphology, which restricts T-cell access to these hepatomas. As T-cells 
have easier access to the confluent Huh-7 monolayers, they may be undergoing 
constant entosis and release, which explains why a significant difference in %T-cell 
release is not present between 2 hour and 24 hours incubations (Figure 22).  
 
4.5. The effects of stimuli on T-cell release from Huh-7 
hepatomas 
 
One experiment involved a three hour treatment of Huh-7-T-cell co-cultures with pro-
inflammatory and anti-inflammatory cytokines, growth factors and hypoxic conditions 
(Figure 19). These results showed that most treatments had no significant effect on 
T-cell release compared to the untreated control.  
However, IFNɤ treatment significantly reduced %T-cell release from Huh-7s in 
comparison to untreated controls. Previous work demonstrates that IFNɤ has a role 
in stimulating hepatic inflammation and aggravating liver damage(28). Furthermore, 
hepatocyte entry and degradation of self-reactive CD8+T-cells recently demonstrated 
a novel tolerogenic mechanism within the liver(27). This decrease in T-cell release 
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may represent another form of tolerance whereby T-cells ‘hide’ in hepatocytes in 
order to avoid exacerbating the inflammatory response induced by IFNɤ.  
4.6. CD2 downregulation on CD4+T-cells in hepatoma co-
cultures 
 
Results from Figure 22 show that CD2 surface expression on T-cells is lost 
significantly during co-culture. This effect increases in the presence of pro-
inflammatory cytokine IL-6. Both these antibodies were used at saturating 
concentrations pre-determined by titration, which suggests that CD2 expression is 
being down-regulated or lost in the presence of co-cultures with hepatoma cell lines.  
The reduced expression of CD2 on CD4+T-cells in the presence of hepatomas could 
be a response to cytokines secreted by the hepatomas (HepG2-CD81s/Huh-7s). 
Hepatocytes are known to produce IL-6 and TNFα(8, 13). These inflammatory 
cytokines may be responsible for inducing CD2 downregulation on T-cells.   
CD2 has been implicated in the induction of T-cell anergy(29, 30), where previous 
experiments show that down-modulation of CD2 on T-cells can result in reduced 
proliferation and IL-2 production(29). Re-expression of CD2 can then restore these 
functions(29, 30). The inflammatory conditions may be inducing anergy in the CD4+T-
cells, therefore increasing CD2 downregulation on T-cells and reducing their IL-2 
production. This describes a possible tolerogenic mechanism for T-cells in the liver, 
where further inflammation is prevented.  
CD2 is also required for T-cell adhesion to APCs via the cell adhesion molecules 
CD58 (LFA-3) and CD59(29, 31). If T-cells are unable to bind to other cells it makes 
them more difficult to activate which again explains CD2-downregulation as a 
tolerogenic function of T-cells in the presence of inflammation. 
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4.7. Future work 
 
This work has optimised a flow cytometry based assay for the detection of T cells 
released by hepatomas in vitro. Expansion of this study would lead to greater 
confidence in the results obtained from this experiment and would provide a clearer 
understanding towards the reasons for T-cell entosis and release from hepatocytes. 
The data in the experiment was collected using flow cytometry. It would be beneficial 
however, to confirm these results using a different method. To do this one could to 
set up an overnight experiment to visualise the release of violet CD4+Tcells from 
green hepatomas using a Zen confocal microscope. The effect of treatment can then 
be recorded visually and a Z-stack can confirm internalisation of the T-cells within the 
hepatomas. 
Hepatoma cells are cancer derived and so may differ from the in vivo situation in 
important aspects. Recent studies show that many proteins are down-regulated in 
hepatoma cell lines compared to primary hepatocytes(14). In order to be able to 
translate this T-cell entosis model to an in vivo situation, the release assay should be 
repeated using primary hepatocytes. 
The results from this study show that cytokines, growth factors and hypoxic 
conditions do not significantly affect the percentage release of CD4+T-cells from 
hepatoma cell lines. It may be that another factor induces increased release of T-
cells such as a viral infection. Further release assays could be repeated on co-
cultures infected with a viral infection, which could mimic hepatitis based model. It is 
also possible T-cell release responses to stimuli were not observed because they 
require a specific environment requiring a combination of stimuli rather than a single 
stimulus alone. It is possible that percentage T-cell release from hepatomas may 
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differ to controls when stimuli are used in combinations with each other, which could 
also be used to closely mimic various in vivo situations. 
Lastly, future experiments would measure the % of entosis prior to measuring the 
%T-cell release so that all experiments can be made relative and comparable to each 
other. From this study the % of T-c0ells internalised via entosis is unknown. If the 
numbers of entosis events are low at the beginning of the assay, it may explain why 
%T-cell release has also been low throughout the study.  
4.8. Conclusion 
In conclusion, this study has optimised a protocol to quantify the percentage of 
CD4+T-cell release from hepatomas following entosis, however further work is 
required to fully investigate the causes of entosis and CD4+T-cell release from 
hepatocytes. Although most treatments did not significantly affect the percentage 
release of T-cells from hepatomas, shorter incubation times with stimuli showed a 
larger % of T-cell release from HepG2-CD81s compared to 24 hour treatments, 
demonstrating how the organisation of hepatomas may influence the speed and 
frequency at which entosis and release occurs. Understanding the reasons for 
entosis and release of CD4+T-cells is important; so that the T-cells may be 
manipulated therapeutically to function against the development of infections and 
diseases in the liver such as HCV. 
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Abstract 
 
E3 ubiquitin ligases have been identified as key regulators of the immune system. 
They function in T-cell tolerance by targeting molecules for degradation, thereby 
affecting T-cell signalling and activation. By understanding the role of E3 ubiquitin 
ligases in different T-cell subsets, we may be able to manipulate them therapeutically 
to stop or promote T-cell activation, thereby preventing development of autoimmune 
diseases and cancer respectively.  
This study induces anergy in human CD4+T-cells through plate-bound anti-CD3 
antibody stimulation. Anergy in anti-CD3 stimulated cells was determined by 
quantifying the number of proliferating T-cells by flow cytometry following a 
secondary anti-CD3.28 stimulus. Quantitative RT-PCR was also used to establish 
differences in E3 ubiquitin ligase expression between T-cell subsets. Results showed 
some induction of anergy in anti-CD3 stimulated T-cells.  
When comparing E3 ubiquitin ligase expression between different T-cell subsets, 
many of the genes were not detectable. This may be due to large amounts of cell 
death during assays resulting in low cDNA recovery and insufficient material to detect 
gene expression. This study concludes that further work is required to confirm the 
anergic state of the T-cells. Furthermore, in order to accurately compare E3 ligase 
expression between T-cell subsets, RT-PCR needs to be repeated using more 
material.  
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1. Introduction 
1.1. The role of T-cells in tolerance and autoimmunity 
 
Immunological self tolerance occurs when the body’s immune system prevents 
mounting an immune response to self antigens. CD4+T-cells are able to mount strong 
immune responses to foreign antigens and are mostly unresponsive to self 
antigens(1). Many autoimmune diseases occur due to a breakdown of tolerance 
within the CD4+T-cell population(2). Two types of T-cell tolerance exist: central 
tolerance (induced in the thymus) and peripheral tolerance (induced in the secondary 
lymphoid and peripheral tissues)(2, 3).  
1.1.1. Central Tolerance and nTregs 
 
Central tolerance occurs largely throughout fetal life, and involves the deletion of T-
cells which bind self-antigen with high affinity(1). Deletion occurs prior to T-cell 
maturation, preventing self-reactive T-cells from leaving the thymus and causing 
autoimmunity(1, 4).  
Self-antigens are processed and presented by thymic antigen presenting cells 
(APCs) in association with self-MHC (Major Histocompatibility Complexes)(1, 4, 5). 
First, T-cells in the thymus undergo positive selection where the T-cell receptors 
(TCR) bind to self-MHC molecules with sufficient affinity. They are then selected to 
develop into a single positive CD4+CD8- or CD4-CD8+ thymocytes(1, 5). T-cells which 
do not show sufficient affinity to self-antigens are deleted via ‘death by neglect’(1, 4, 
5). Negative selection occurs next whereby T-cells with a high affinity for self-MHC 
molecules undergo apoptotic cell death(1, 4, 5), preventing dangerous self-reacting 
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T-cells from escaping into the periphery and causing damage. The thymic selection 
process is illustrated by Figure 1. 
Figure 1 – Central tolerance in the thymus. (A) Death by neglect - double 
positive T-cell does not recognise APC and MHC-self-peptide complex. This 
causes apoptosis. (B) Positive selection - low-affinity interactions between the 
thymocyte and peptide-MHC complex leads to development of a single positive 
T-cell which escapes to the periphery. (C) Negative selection - Strong binding 
between the thymocyte and MHC-peptide complex leads to apoptosis. This 
prevents self reactive T-cells from becoming single positives and escaping into 
the periphery to cause host damage. (5) 
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Impaired development and function of naturally arising CD4+CD25+ Treg cells 
(nTregs), has been associated with several autoimmune diseases(6). nTregs arise 
from T-cell progenitors in the bone marrow and develop in the thymus. Here they 
are positively selected on an intermediate TCR-affinity strength which lies between 
that required for the positive and negative selection for conventional T-cells(7, 8). 
nTregs then migrate into the periphery where they contribute to 5-10% of the 
mature peripheral CD4+T-cell population(8). They are characterised by their 
expression of the transcription factor forkhead box p3 (Foxp3). The survival of 
nTregs in the periphery is dependent on exogenously produced IL-2(9), whereas 
their function depends on the production of cytokines such as IL-10, IL-35 and 
TGFβ, which exert suppressive effects on conventional T-cells(4).  
1.1.2. Mechanisms of Peripheral tolerance 
Not all self-antigens are expressed in the thymus during lymphocyte development, 
allowing some self-reactive lymphocytes to escape into the periphery(4). This 
highlights the importance of peripheral tolerance; when lymphocytes first encounter 
self-antigens outside the thymus (e.g. food antigens)(4). Peripheral tolerance 
processes involve deletion or hyporesponsiveness of self-reactive T-cells, which 
meet self-antigens outside the thymus(4, 10). It includes the action of regulatory T-
cells, deletion of self-reactive T-cells, anergy and immune ignorance(1, 4). 
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1.1.2.1. Immune Ignorance 
 
Immune ignorance describes the process when self-reactive T-cells fail to react to 
their autoantigen(4).This occurs when antigens are present at low concentrations, 
therefore are incapable of overcoming the lymphocyte-receptor threshold to trigger a 
response(11). Furthermore, some self-antigens are present in immune-privileged 
sites. These Immune-privileged sites describe locations which are tolerant to the 
presence of antigens without responding with a potentially damaging inflammatory 
response(4, 11). Immune-privileged sites include the brain, the testes and the eye(4).  
1.1.2.2. CD4+CD25+T-cells (iTreg Cells) 
 
ITreg CD4+CD25+ cells (inducible regulatory T-cells) are distinct from nTregs and 
form in the presence of chronic inflammation and disease(12). They mature from 
naïve CD4+T-cells in the periphery in response to TGFβ, where they acquire the 
expression of CTLA4 and CD25 markers, and upregulate the transcription factor 
FOXP3(12). Like nTregs, iTregs are involved in tolerance to self-antigen and 
suppression of the immune system(7). More specifically, they suppress T-cell 
proliferation and autoimmune reactions through IL-10 and TGFβ production, causing 
apoptosis of effector T-cells and blocking co-stimulation and maturation of dendritic 
cells(13). The development and action of Tregs are presented in Figure 2.  
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Figure 2 - (8) nTregs (top) differ from naïve conventional T-cells in the thymus. 
The cell surface markers expressed by nTregs are indicated in the top box 
however none of these markers are solely expressed by Tregs and can also be 
located on activated conventional T-cells. iTregs (bottom) can develop from T-
cell precursors in the periphery in the presence of IL-10 and TGFβ secreted 
from APCs (DCs and macrophages). iT-regs share similar surface markers to 
nTregs, and can be induced to form Foxp3- Tr1 cells or Foxp3+ Th3 cells.  
 
 
 
CD4+Foxp3+ Treg cells differ from CD4+Foxp3- conventional CD4+T-cells. The 
conventional T-cell population is diverse and consists of subpopulations 
characterised according to cytokine production(14). They include the populations 
Th1, Th2 and Th17, wherein central memory and effector memory subpopulations 
exist(15).  
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1.1.2.3. Anergic T-cells 
1.1.2.3.1.  CD4+T-cell activation 
 
Two signals are required for CD4+T-cell activation and the mounting of an effective 
immune response. An example of CD4+ T-cell activation is presented in Figure 3 
below. 
 
Figure 3 - (16, 17) Signal 1 occurs when the TCR binds to the MHCII-peptide 
complex presented by APCs(17). The MHCII molecule is restricted to 
professional APCs (dendritic cells, B cells and macophages)(10, 17). Signal 2 
occurs through co-stimulation. The co-stimulatory receptor CD28 is 
constitutively expressed by naïve CD4+T-cells and binds to co-stimulatory 
ligands CD80/CD86 on APCs(17). Both the TCR and co-stimulatory molecule on 
the CD4+T-cells must simultaneously engage with the MHCII-peptide complex 
and the co-stimulatory molecules on the APC, in order for effective T-cell 
activation to occur. 
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1.1.2.3.2. CD4+T-cell anergy 
 
Anergy is a negative regulatory process of T-cell activation(10, 18). By understanding 
the mechanism of anergy, unwanted T-cell activation may be targeted, therefore 
preventing the development of autoimmune disease(10). By definition, anergy is a T-
cell intrinsic state of unresponsiveness which occurs when T-cells are activated 
through the TCR in the absence of co-stimulation(10, 17). Upon re-stimulation with 
antigen, anergic T-cells remain viable, but demonstrate long lived 
hyporesponsiveness, including defects in cell-cycle progression and effector 
function(17) (See Figure 4). 
 
Figure 4 – (Left) Normal T-cell activation requiring Signal 1 (MHC-peptide with 
TCR) and Signal 2 (CD60/86 with CD28). (Right) Anergy occurs in the presence 
of Signal 1 but absence of Signal 2 (no CD80/86-CD28 co-stimulation). This 
means that the T-cell is not efficiently activated therefore enters an ‘anergic’ 
state(19). 
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Anergy has been identified in vivo and in vitro(17). In vitro, T-cells undergo clonal 
anergy, where they are unresponsive to recall stimulation in the absence of co-
stimulation(10, 17). Clonal anergy is characterised by reduced IL-2, IL-3 and IFN-ɤ 
secretion and reduced proliferation(10, 17, 20). It was first characterised in CD4+T-
helper cells stimulated through the TCR in the absence of CD28 co-stimulation(10, 
17), and is reversible with strong stimuli or exogenous IL-2/IL-15 upon re-
stimulation(10, 17, 20). Previous data suggests that induction of clonal T-cell anergy 
in naïve T-cells is difficult, however may be possible when induced via plate bound 
anti-CD3 mAb in the absence of soluble anti-CD28 mAb(10, 21). Various other 
methods are also used to induce T-cell anergy in vitro, including the mitogen 
concanavalin A and altered peptide ligands with lower avidity TCR ligation(17).  
 In vivo anergy models are termed adaptive tolerance(10). Adaptive tolerance results 
from peripheral T-cells being challenged by superantigen or specific peptides which 
results in T-cell activation in the absence of antigen-APC stimulation(17). One in vivo 
study showed that antigen challenge of TCR-transgenic mice caused large amounts 
of T-cell death(10). The T-cells which survived were anergic and displayed reduced 
proliferation and IL-2 production, just as demonstrated by in vitro models(10).  
Anergy in naïve T-cells can be induced in vivo, however may not always be induced 
in naïve T-cell in vitro(10). Furthermore, the anergic state of T-cells in vivo cannot be 
rescued by IL-2, and instead recovers over time due to loss of the antigen from the 
periphery(10). 
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1.2. The ubiquitination pathway 
Ubiquitin is a 76-amino-acid globular molecule present in all tissues, which 
determines the fate of the protein it is attached to(10, 20). Normally, ubiquitin targets 
proteins for degradation and recycling via the 26S proteasome(10, 20, 22). However 
other purposes of protein ubiquitylation include re-directing proteins within the cell, 
conformational changes of proteins and protein stabilisation(10, 20).  
Ubiquitin is part of the ubiquitination pathway. The transfer of ubiquitin to target 
proteins involves coordination between the ubiquitin enzymes: E1, E2 and E3(10, 20, 
22, 23). De-ubiquitylating enzymes and ubiquitin-binding proteins are also involved in 
this pathway(20, 23). Figure 5 illustrates the steps involved in the ubiquitin-
proteasome pathway. 
 
 
Figure 5(10) – The ubiquitin-proteasome pathway. Ubiquitin is activated in an 
ATP-dependant manner by E1 ubiquitin-activating enzyme. This activated 
ubiquitin is transferred to an E2 ubiquitin-conjugating enzyme (E2 ubiquitin 
transferase). The E2 enzyme binds to the recruitment domain of E3 ubiquitin 
ligase (such as the RING/HECT domain), which brings together the substrate 
and activated ubiquitin. The ubiquitinated protein can now be targeted for 
proteasome degradation. De-ubiquitylating enzymes can remove ubiquitin from 
the protein substrate(10). 
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1.3. E3 Ubiquitin protein ligases and their role in T-cell anergy 
E3 ubiquitin ligases consist of a large complex superfamily of >500 enzymes(17) 
which catalyse the covalent bonding of the ubiquitin molecule to the target protein via 
the ubiquitination pathway(10, 17). In recent years, E3 ubiquitin ligases have been 
identified as critical in the regulation of T-cell responses by influencing T-cell 
signalling pathways(10).   
Upregulation of E3 ubiquitin ligase genes Cbl-b(24), GRAIL(18) and ITCH(24) have 
been associated with T-cell activation and anergy(10, 20). However, recent research 
has identified TRAC1 (RNF125)(25), NEDD4(26), Peli1(27) and TRAF6 to also be 
involved in T-cell activation(26-28), suggesting that these genes may also be 
involved in maintaining the anergic state of T-cells. 
1.3.1. Cbl-b 
Cbl-b is a 982-amino acid containing protein with high sequence homology to 
CBL(10, 24). This RING-type E3 ligase was the first to be identified to have a role in 
in vivo tolerance and T-cell activation(10). Previous research shows that peripheral T-
cells from Cbl-b-/- mice express increased IL-2 secretion and hypoproliferation 
following stimulation compared to wild-type cells(20). Cbl-b-/- mice also develop 
spontaneous autoimmunity by 6 months of age(10, 23, 24). Furthermore, studies 
show that murine Cbl-b-/- T-cells are resistant to anergy induction in vitro and in 
vivo(22). Collectively, this data indicates that Cbl-b is involved in negative regulation 
of T-cell activation in the periphery and anergy. 
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1.3.2. GRAIL 
GRAIL (RNF128), is a 428-amino acid type1 transmembrane protein which contains 
an extracellular protease-associated domain, a cytosolic coiled domain and RING-
finger domains(10, 18). GRAIL is upregulated in ionomycin-induced anergic murine 
T-cells(10, 18) and constitutive expression of GRAIL has been associated with 
anergy in T-cells(23). Further studies show that overexpression of GRAIL in naïve 
CD4+T-cells abolishes IL-2 production and proliferation upon peptide-APC 
stimulation(17). This data demonstrates the suppressive role of GRAIL in T-cell 
activation and its role in anergy. 
 As with Cbl-b and ITCH, GRAIL also contributes to Treg function and is highly 
expressed in nTregs(20, 23). Results show that GRAIL expression levels correlate 
with the immunosuppressive activity of murine Treg cells induced in vivo through 
superantigen exposure(23). These results indicate that GRAIL also has a vital 
function in T-cell tolerance(10).  
1.3.3     ITCH 
ITCH is a 864-amino acid cytosolic E3 ubiquitin ligase(10) which plays a role in TCR 
signalling and T-cell activation through ubiquitination(10). This is demonstrated by in 
vitro studies, where ITCH-deficient cells show enhanced proliferation and activation 
on TCR-engagement(23). Furthermore, in vivo studies show ITCH mutations in 18H 
mice cause persistent itching of the skin and lymphoproliferative disease, indicating 
its role in peripheral tolerance(10, 24). ITCH-/- mice are also resistant to ionomycin-
induced anergy and their CD4+T-cells are resistant to Treg-dependant 
immunosupression(10, 20, 23, 24) reinforcing the importance of ITCH in tolerance 
and as a negative regulator of T-cell activation. 
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1.3.4. NEDD4, TRAC1 and PELI1 
TRAC-1 (RNF125) contains an N-terminal RING-finger domain(25). Investigation into 
high expression of TRAC-1 in lymphoid tissues has shown that antisense 
oligonucleotides reduce TRAC-1 mRNA levels in primary T-cells, and inhibit T-cell 
activation in response to TCR cross-linking(25). This indicates that TRAC-1 is a 
positive regulator of T-cell activation(25), and therefore its expression may be 
downregulated in anergic T-cells.  
Recent studies have revealed that Nedd4 also positively regulates T-cell 
activation(10, 20). Although Nedd4-/- T-cells develop normally, they show reduced 
proliferation and IL-2 production(26). Nedd4-/-T-cells also contain more of the E3 
ubiquitin ligase Cbl-b. Studies show that Nedd4 promotes the ubiquitin-mediated 
degradation of Cbl-b in activated T-cells and promotes the conversion of naïve T-
cells into activated T-cells(20, 26). In other words, Nedd4 can be described as a 
positive regulator of T-cell activation(23), which functions by targeting an E3 ubiquitin 
ligase which negatively regulates T-cell activation.  
Peli1 belongs to the Pellino family of E3 ubiquitin ligases and is one of three 
members (PELI1, 2 and 3)(27). The function of PELI depends on the C-terminal 
RING domain. Investigations show that Peli1 is crucial as a negative regulator of T-
cell activation and in preventing autoimmunity(27). Peli1 deficiencies cause 
hyperactivation of T-cells which are resistant to Treg and TGFβ supression(27).  
Furthermore Peli1-/- mice develop autoimmunity and accumulation of the transcription 
factor c-Rel, which has important roles in T-cell activation(20, 27). These results 
highlight the importance of Peli1 in maintaining peripheral tolerance(17, 27).  
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1.4. Aims & objectives  
The aim of this study is to construct a protocol to induce anergy in human CD4+T-
cells using existing literature. Furthermore, the expression of E3 ubiquitin ligases will 
be compared between Tregs, conventional CD4+T-cells, anergic CD4+T-cells and 
non-anergic CD4+T-cells through the use of CD4+T-cell isolation assays and 
quantitative RT-PCR. This will clarify whether E3 Ubiquitin ligases are associated 
with T-cell anergy and are differentially expressed between different T-cell 
phenotypes.  
We hypothesise that all the E3 ubiquitin ligases which are negative regulators of T-
cell activation will be upregulated, and positive regulators of T-cell activation such as 
RNF125 and Nedd4 will be downregulated in anergic and Treg populations. This is 
because the hyporesponsive and tolerogenic functions of anergic T-cells indicate that 
the threshold for T-cell activation in these subsets may be higher compared to non-
anergic T-cells and CD4+CD25-T-cells. 
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2. Methods 
6. The T-cell anergy assay 
 
The T-cell anergy assay was performed over a period of 8 days. On Day 0, PBMCs 
were isolated from human peripheral blood using Ficoll. CD4+CD25+ (Conventional T-
cells) and CD4+CD25- cells (Tregs) were isolated using a CD4+CD25+ Treg Isolation 
Kit (MACS, Miltenyi Biotec, UK) as described in 2.2. Pellets of Tregs and a proportion 
of conventional T-cell pellets were stored in a -80°C freezer for future experiments 
via PCR. The remaining conventional T-cells were incubated in complete media 
alone, or were treated with plate-bound anti-CD3 mAb or plate-bound anti-CD3 mAb 
with soluble anti-CD28 antibody. The treatment groups were incubated for 24 hours. 
On Day 1 the T-cells were washed and rested in complete media until Day 4. On Day 
4 T-cells from all the treatment groups were stained with proliferation dye then either 
re-stimulated (using anti-CD3.28 Dynabeads) or not re-stimulated. 3 hours following 
re-stimulation samples of each treatment group were taken and frozen down for 
future PCR experiments (Figure 7). The remaining T-cells were incubated until Day 8 
where they were analysed for T-cell proliferation via flow cytometry. The process of 
this assay is displayed by Figure 6.  
Figure 6 – Overview of anergy assay (Day 0-8). Boxes headed cDNA indicates 
where cell pellets will be frozen and cDNA isolated for PCR. 
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2.2. Isolating CD4+CD25- and CD4+CD25+ T-cells from human 
peripheral blood 
 
Two 50ml universal tubes were prepared with 125µl of heparin and 25ml of blood 
from the same donor. The blood was diluted with an equal volume of RPMI-1640 
(1%GPS, 1% hepes, Sigma-Aldrich Life Science, UK) and prepared with Ficoll (GE 
Healthcare Life-Sciences, UK) to isolate PBMCs according to the manufacturer’s 
instructions. 
The PBMC buffy coat layer was harvested and washed twice with RPMI before being 
counted and 50µl was isolated for a purity check. The CD4+ T-cells were negatively 
selected from CD4- cells using a CD4+CD25+ Treg Isolation Kit (MACS, Miltenyi 
Biotec, UK). This involved using MACS buffer (PBS, 0.1% BSA, 2mM EDTA (Sigma-
Aldrich, UK, E7889)), Biotin antibody cocktail, anti-biotin microbeads (Miltenyi Biotec 
130-045-101, UK) and an LD column (Miltenyi Biotec 130-042-201, UK) according to 
the manufacturer’s instructions.  
Next the CD4+CD25- cells were separated from the CD4+CD25+ T-cells using MACS 
buffer and an MS column (Miltenyi Biotec, UK) according to the manufacturer’s 
instructions. 50µl of the CD4+CD25- and CD4+CD25+ cells were stored for flow 
cytometry purity checks. 
The cells were counted and cell suspensions of between 100,000 and 200,000 
CD4+CD25+ and CD4+CD25- T-cells were centrifuged. The supernatant was 
discarded and the pellet was frozen in a -80°C freezer for future PCR experiments.  
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2.3. Stimulating CD4+CD25- with plate bound anti-CD3 
antibody 
 
Three conditions were tested in these experiments: unstimulated (resting) T-cells, 
anti-CD3 antibody treated T-cells and anti-CD3.28 antibody treated T-cells. The anti-
CD3 human antibody (eBiosciences, clone:0KT3, UK) was diluted to a concentration 
of 2µg/ml with sterile PBS(29, 30). 1ml of this anti-CD3 solution was added 2 wells on 
a 24-well plate and left to incubate at 37°C for 1 hour (29, 30). Following incubation 
the antibody solution was washed from the wells three times using sterile PBS. 
 From the T-cell isolation, 2-3million conventional CD4+CD25- T-cells suspended in 
1ml RPMI, were plated into each of the three wells (including the plate-bound anti-
CD3 coated wells). Soluble anti-CD28 human antibody (eBiosciences, clone:CD28.2, 
UK) was added to one of the wells to form a final concentration of 2µg/ml (31). The 
plate was incubated for 24 hours at 37°C. following incubation, the T-cells were 
transferred to Falcon tubes and washed in complete RPMI-1640 media (1%GPS, 1% 
hepes,  10%HIFCS) (Sigma-Aldrich Life Science, UK) before being transferred to a 
fresh 24-well plate where they were rested for 3 days in the incubator at 37°C(31). 
2.4. Staining the CD4+CD25- T-cells with proliferation dye 
The T-cells were transferred to falcon tubes and washed once with PBS to remove 
any serum. They were then re-suspended in room temperature PBS at twice the final 
required concentration. The cell proliferation dye (eFluor 450, eBioscience, 65-0842, 
UK) was diluted in PBS to form a 20µM solution, before being added to the cell 
suspension in a 1:1 dilution, and left to incubate in the dark at 37°C for 10 minutes. 
Cold complete media was used to stop labelling and the cell suspension was 
incubated on ice for a further 5 minutes before being washed twice in complete 
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media. After the washes, the cells were counted, re-suspended in complete media 
and plated on a round-bottom 96-well plate. Each condition was plated three times so 
that T-cells could be harvested at 3 hours following re-stimulation, 4 days following 
re-stimulation and for flow cytometry (Figure 7). 
.  
2.5. Re-stimulating CD4+CD25- T-cells with anti-CD3 & 
anti-CD28 Dynabeads 
 
Anti-CD3.28 human T-activator Dynabeads (Gibco, Life Technologies, UK) were 
used to re-stimulate the three different T-cell conditions. The bead stock solution was 
diluted with complete medium according to the manufacturer’s instructions and 100µl 
of bead solution was added to all the ‘re-stimulated’ wells. Figure 7 demonstrates the 
layout of conditions on the 96-well plate. Figure 8 shows the solutions added to the 
‘stimulated’ and ‘un-stimulated’ wells. The pellets of T-cells harvested at 3 hours 
following re-stimulation and 4 days following re-stimulation were frozen in a -80°C 
freezer for future PCR experiments. Figure 6 illustrates the process of the entire 
assay in the form of a flow diagram. 
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Figure 7 – Diagram demonstrating the treatment groups of T-cells of on a 96-
well plate. The three treatment groups are resting T-cells (initially 
unstimulated), anti-CD3 stimulated T-cells and anti-CD3.28 stimulated T-cells. 3 
days following stimulation these groups were then either re-stimulated with 
anti-CD3.28 beads or not re-stimulated. At 3 hours and 4 days following re-
stimulation, T-cells were harvested and the pellets frozen for future PCR 
experiments 
 
Figure 8 – Diagram demonstrating the contents of re-stimulated and non re-
stimulated wells on the round-bottom 96-well plate. The total volume of a well 
on a 96-well plate did not exceed 200µl. unstimulated wells (left) contain the T-
cell suspension in media. Re-stimulated wells (right) contain media, cell 
suspension and anti-CD3/28 antibody bead solution.  
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2.6. Re-stimulating CD4+CD25- T-cells with anti-CD3 & 
anti-CD28 Antibody 
 
In some experiments, T-cells were re-stimulated via plate bound anti-CD3 and 
soluble anti-CD28 antibody. As previously, the anti-CD3 antibody was diluted from a 
to forma 2µg/ml with sterile PBS. 200µl of anti-CD3 solution was then added to all re-
stimulated wells of the 96-well plate and left to incubate at 37°C for 1 hour. Following 
incubation the antibody solution was washed from the wells three times using sterile 
PBS. 100,000 cells were suspended in complete media containing anti-CD28 
antibody (diluted to form a final concentration of 2µg/ml), and were added to the anti-
CD3 coated wells on the 96-well plate and left to incubate until day 8.  
2.7. Re-stimulating CD4+CD25- T-cells with anti-CD3 & 
anti-CD28 Treg suppressor beads 
 
Other experiments used Treg human suppression inspector beads (MACS, Miltenyi 
Biotec, 130-092-909, UK) to re-stimulate the T-cells. The bead stock solution was 
diluted with complete medium according to the manufacturer’s instructions and 100µl 
of bead solution was added to all the ‘re-stimulated’ wells in the same way as the 
CD3.28 Dynabeads.  
2.8. Isolating cDNA  
A µMACSTMOne-step cDNA Kit (MACS, Miltenyi Biotech, UK) was used according to 
manufacturer’s instructions, to isolate cDNA from sample pellets from anergy assays.  
Cells were lysed with lysis buffer and the cellular DNA was sheared through a 21G 
needle attached to a 1-5ml syringe. The sheared lysate was then spun for 1 minute at 
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x13000g before being applied to the LysateClear column where it was spun for a 
further 3 minutes at x13000g.  
The µMACS column was placed in the magnetic field and prepared with 100µl of 
binding/lysis buffer. Following centrifugation, 50µl of Oligo(dT) Microbeads was 
added to the 1ml of lysate and mixed thoroughly before being added to the column 
matrix. The column was rinsed withLysis/Binding buffer to remove protein and DNA, 
and then rinsed with Wash Buffer to remove rRNA and DNA. Equilibration/Wash 
Buffer was then added to the column matrix.  
The Enzyme Mix was dissolved in 20µl Re-suspension Buffer and also added to the 
top of the column. Sealing solution was added directly on top of the column and the 
thermoMACS Separator was set to 42° and left to incubate for 1 hour. Following 
incubation, the column was rinsed twice again with Equilibration/Wash buffer. 20µl 
cDNA Release Solution was then applied the column matrix and left to incubate for 
10mins at 42°C before the synthesized cDNA was eluted with 50µl cDNA Elution 
Buffer.  
2.9. PCR 
The concentration of cDNA was measured using the Nanodrop2000/2003 
Thermoscientific and the cDNA samples were aliquoted into a 384-well PCR plate 
with master-mix (Fast start universal probe master, Rox, Roche Applied Science, UK) 
GAPDH reference probe (Hs02758991_g1) (TaqMan Gene Expression Assays, 
Applied Biosystems, UK), RNase free water and the target primer probe. Target 
probes included RNF125 (Hs00215201_m1), RNF128 (Hs00226053_m1), ITCH 
(Hs00395201_m1), PELI1 (Hs00900505_m1), Nedd4 (Hs00406454_m1), CBLB 
(Hs00180288_m1)) (TaqMan Gene Expression Assays, Applied Biosystems, UK). 
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The reaction volume was 5µl. Each condition was plated as a triplicate and the 
control consisted of 2.5µl master mix with 2.5µl RNase free water. The PCR was run 
on the Light Cycler480 II (Roche Applied Biosystems) for 45 cycles before being 
analysed via basic relative quantification. The cycle conditions are shown in Table 1. 
Stage Cycles 
Temp 
°C 
Hold Time 
(h:min:sec) 
Ramp 
Rate 
(°C/s) 
Pre-incubation 1 95 00:10:00 4.4 
Amplification 50 
95 00.00.15 4.4 
60 00.01.00 2.2 
72 00.00.01 4.4 
Melt curve 1 
95 00.00.10 4.4 
40 00.00.30 2.5 
80 continuous 0.06 
Cooling 1 40 00.00.10 2 
 
Table 1 – PCR cycle conditions performed by the Light Cyler480 II to detect E3 
ubiquitin ligase gene expression in T-cell subsets 
 
2.10. Statistics  
AccuCheck counting beads (Life Technologies, Invitrogen, UK) were added to 
samples from anergy assays according to manufacturer’s instructions prior to flow 
cytometry. This allowed the number of proliferated cells counted via flow to be 
calculated in order to make all results from the same experiment relative. These 
results were then plotted on a bar graph using the mean. Error bars presented in 
graphs displayed the SEM. Results which displayed significant differences were 
marked with a * where p<0.05, ** where p<0.01 and *** where p<0.001. 
 
The ΔCt values and 2^-ΔCt values were calculated from the PCR results. The 
replicate 2^-ΔCt values were then plotted on a bar graph to display the mean and 
standard error of the mean (SEM) which was calculated via Prism. 
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No stimulation
Anti-CD3.28 Antibody Anti-CD3.28 Dynabeads
Anti-CD3.28 Treg beads
9a.
9b.
3. Results 
3.1. Methods used to initially stimulate conventional CD4+T-
cells affects T-cell proliferation 
 
Different methods were used to stimulate conventional CD4+T-cells to define 
which method could be used in anergy assays to induce T-cell proliferation, but 
allow T-cells to return close to rest by day 4 (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9- a.  Flow diagrams and histograms demonstrating effects of anti-
CD3.28 stimulation methods on CD4+T-cell proliferation. T-cells were 
stimulated for 4 days. The T-cell population was gated  and the proportion of 
proliferating T-cells calculated using counting beads. b. Graph comparing 
effects of anti-CD3.28 stimulation methods on numbers of proliferating CD4+T-
Cells (Day 4). Each condition was performed in triplicates therefore the graph 
shows means and the error bars represent the SEM where n=3. Significant 
differences to the untreated control are represented by * where p<0.05, ** 
where p<0.01 and *** where p<0.001. The stimulation methods used in this 
experiment were Dynabeads, Treg suppressor beads and CD3.28 antibody. 
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Gate AR in Figure 9a shows that the non-stimulated CD4+T-cell population 
experiences the lowest % T-cell proliferation. Figure 9b shows that the antibody 
stimulated population demonstrates a significantly higher amount of proliferation 
compared to unstimulated controls where p=0.049. T-cells stimulated with Treg 
suppressor beads induced significantly higher T-cell proliferation numbers compared 
to unstimulated controls, where p=0.004. Dynabead stimulation induced the highest 
significant T-cell proliferation number compared to unstimulated populations where 
p=0.0009. 
 The results show that antibodies are the most effective at both stimulating the T-cells 
and allowing them to return to rest by Day 4. 
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3.2. Anergy induction is not dependant on the method of 
CD4+T-cell re-stimulation  
 
This experiment was performed to determine whether re-stimulating T-cells via 
different methods following initial antibody stimulations, would affect T-cell 
proliferation numbers and trends in the data (Figure 10). 
 
 
Figure 10– Results from Experiment 4 anergy assay at Day 8, where different 
methods of re-stimulation are used (n=1). T-cells are stimulated using anti-CD3 
or anti-CD3.28 antibody at Day 1, then re-stimulated (CD3.28) using antibody, 
Dynabeads or Treg suppressor beads at Day 4. Results demonstrate the 
number of conventional CD4+T-Cells which have proliferated 4 days after re-
stimulation. 
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Figure 10 shows where there is no re-stimulation, the anti-CD3.28 stimulated CD4+T-
cells from day 4, are still proliferating at Day 8. The proliferation numbers of this 
population are higher compared to the resting and anti-CD3 stimulated populations 
which have also not been re-stimulated.  
In the antibody re-stimulated populations, anti-CD3 stimulated groups contain the 
lowest number of proliferating cells, with the resting and CD3.28 stimulated 
population showing increased proliferation respectively. 
The numbers of proliferating cells induced by Dynabead re-stimulated populations 
were the highest compared to other re-stimulation methods and the non-re-stimulated 
control populations. Dynabead re-stimulation of resting and anti-CD3 stimulated T-
cells induce a similar level of T-cell proliferation with the number or proliferating cells 
increasing from resting and anti-CD3 stimulated populations respectively. Anti-
CD3.28 Dynabead stimulated populations induced the highest T-cell proliferation 
number. Collectively, the trends in the data from the Dynabead re-stimulated 
populations were repeated in Treg bead re-stimulated and non-re-stimulated 
populations. 
Overall this data shows that Dynabeads induce the highest number of T-cell 
proliferation in all three treatment groups without affecting the trend in the data, 
implying that if anergy exists, it is not broken by Dynabead re-stimulation. Therefore, 
Dynabead re-stimulation was used for the remainder of the anergy assays. 
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Resting CD4+T-cells
CD3 stimulated CD4+T-cells 
CD3.28 stimulated CD4+T-cells
Resting CD4+T-cells 
CD3 stimulated CD4+T-cells
CD3.28 stimulated CD4+T-cells
Not re-stimulated Re-stimulated
3.3. Re-stimulated conventional CD4+T-cells initially 
stimulated via anti-CD3 antibody proliferate less 
compared to those initially stimulated with anti-CD3.28 
antibody. 
 
In order to visualise the effects of initial stimulation and re-stimulation on CD4+T-cells, 
and anergy assay was conducted and presented in dot plots in Figure 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Dot plot results from Experiment 1 (Day 8) demonstrating the 
degree of T-cell proliferation when cells undergo no initial stimulation, anti-CD3 
stimulation only, or anti-CD3.28 stimulation only. These populations are either 
re-stimulated by anti-CD328 Dynabeads or not re-stimulated at Day 4. Results 
were collected via flow cytometry on Day 8. 
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Results from Figure 11 show that the majority of unstimulated resting cells with and 
without re-stimulation die. An increased population of CD4+T-cell survive with anti-
CD3 stimulation alone, with an even higher population of T-cells surviving with initial 
stimulation of anti-CD3.28. 
Anti-CD3.28 re-stimulation of the anti-CD3 and anti-CD3.28 stimulated groups, 
induce increased T-cell proliferation in these populations respectively. The T-cell 
death which exists upon re-stimulation correlates with this increase in T-cell 
proliferation, reflecting activation-induced cell death. 
Results show that T-cell survival increases with increased stimulation, implying that 
CD3.28 stimulation induces full activation and CD3 stimulation induces partial 
activation of CD4+T-cells.  
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3.4. Anergy is variably induced in anti-CD3 stimulated cells 
 
Multiple anergy assays were performed to compare T-cell proliferation numbers 
between treatment groups, to identify whether anergy may have been induced 
(Figure 12).  
 
 
 
 
 
 
 
 
 
 
Figure 12- a. Results from anergy assays at Day 8, where n=1.  
 Shows the number of proliferating cells in unstimulated, CD3 and CD3.28 
stimulated T-cell populations, 4 days after Dynabead anti-CD3.28 re-
stimulation. b. Graph showing the % of anti-CD3.28 re-stimulated, proliferated 
T-cells from anergy experiments 1-5 (Figure 11a). Each value is presented as a 
percentage of the anti-CD3.28 initially stimulated, re-stimulated population 
(100%) and averaged. Error bars represent the SEM. n=5.  
** demonstrates a significant difference where p<0.01. 
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In all experiments shown in Figure 12a the anti-CD3.28 stimulated, re-stimulated 
population demonstrates the highest number of proliferating conventional CD4+T-
cells. Experiments 1, 2 and 4 show that T-cell proliferation is higher in the anti-CD3 
stimulated population in comparison to the resting population. 
 
Where results were averaged and expressed as percentages in Figure 12b, both the 
resting and anti-CD3 stimulated populations showed a significantly lower % of 
proliferating T-cells upon re-stimulation, compared to anti-CD3.28 stimulated 
populations, with p-values of 0.005 and 0.009 respectively. However there was no 
significant difference in percentages between resting and anti-CD3 stimulated 
populations following re-stimulation (Figure 12b).  
 
Overall results indicate that anergy may be induced in some experiments; however 
this anergy induction may be donor dependant. 
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In order to determine the health of the resting population of T-cells, an experiment 
was conducted to count the number of non-proliferated cells from the stimulated, 
non-re-stimulated treatment groups (Figure 13). 
 
 
 
Figure 13 – Results from Experiment 4 demonstrating the number of non-
proliferated cells. T-cells were treated at Day 1 with anti-CD3 or anti-CD3.28 
antibody (untreated control). These populations were  not re-stimulated. The 
number of non-proliferating cells were quantified using counting beads and 
flow cytometry at Day 8.  
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Figure 13 shows that the lowest numbers of non-proliferated cells were found in the 
resting non-re-stimulated population, with an increasing number of non-proliferated 
cells in the anti-CD3.28 and anti-CD3 stimulated populations respectively. 
The low number of viable non-proliferated resting cells implies that this population 
may be dying or non-functional therefore making it more probable that anergy may be 
induced in previous experiments. 
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3.5. The CD4+CD25+ and CD4+CD25- T-cells isolated from 
peripheral blood has high purity 
 
Percentage purities of Tregs and conventional isolated T-cells were checked to 
ensure that the PCR samples were not contaminated with other cell subsets 
(Figure 14). 
 
 
Figure 14 – Histograms and dot plots representing a purity check from 
CD4+CD25- and CD4+CD25+ T-cell isolations taken from human peripheral 
blood. (Left) Represents the purity of the entire CD4+T-cell population. (Top 
right) indicates the purity of the conventional CD4+T-cell population. (Bottom 
right) demonstrates the purity of the Treg population. 
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Figure 14 demonstrates that the total CD4+T-cell population was 95.33% pure. The 
purity of CD4+CD25- T-cells was 95.63% and the percentage purity of CD4+CD25+T-
cells (Tregs) was 56.91%, which shows that the CD4+CD25+population were 
enriched with Treg cells. 
These results however, indicate that the Treg population is not as pure as the 
conventional T-cell population, and is contaminated with some CD4+CD25+ T-cells. 
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3.6.  Peli1 is expressed to a similar degree in both Treg cells 
and conventional CD4+T-cells 
 
Quantitative RT-PCR was performed to detect the expression of E3 ubiquitin ligase 
genes in Tregs and conventional T-cells, to assess whether E3 ligase expression 
was specific to the function of these T-cell subsets (Figure 15).  
 
 
Figure 15 – A graph comparing the expression of 6 anergy related E3 ubiquitin 
ligase genes between conventional CD4+T-cells (CD4+CD25-) and Tregs 
(CD4+CD25+). Both these T-cell subsets were isolated from human blood at Day 
0 and frozen. Each condition was repeated in triplicate and displayed as a 
mean. The error bars represent the SEM. The single lines on the graph indicate 
where genes were not detectable (N/D), where the reference gene GAPDH was 
detected however the target anergy gene was not. n=2/3 except where no error 
bars are present in which case n=1. 
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Cbl-b, RNF128 (GRAIL), NEDD4 and ITCH  expression were not detectable in the 
conventional CD4+T-cells isolated at Day 0, but were detectable at a very low level in 
Tregs. E3 ligase genes which were detectable were expressed at very low levels in 
both these T-cell populations. The highest gene expression existed for Peli1 which 
was expressed at similar levels between Tregs and conventional T-cells.   
Where E3 ligase genes were detectable in Tregs but not detectable in conventional 
T-cells, implies that these E3 ubiquitin ligases may have a role in Treg function. 
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3.7. The overall expression of anergy related E3 ligases in 
anti-CD3 stimulated/re-stimulated and anti-CD3.28 
stimulated/re-stimulated conventional CD4+T-cells is low 
 
The raw data curves from the PCR reactions were analysed to explain why some 
E3 ubiquitin ligase genes were not detectable from Figures 15 and 17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16a, b – PCR curves demonstrating raw data. Represents the expression 
of RNF125 and Peli1 respectively against reference gene GAPDH between anti-
CD3 stimulated and anti-CD3.28 stimulated CD4+T-Cells +/- anti-CD3.28 
Dynabead re-stimulation. c,d -Represents expression of RNF125  and Peli 1 
respectively against GAPDH between anti-CD3 stimulated and anti-CD3.28 
stimulated CD4+T-Cells +/- anti-CD3.28 Dynabead re-stimulation. 
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Figure 16 c and d demonstrates that where GAPDH is detected early at ~25 cycles, 
the target genes (Peli1 and RNF125) are detectable at ~10 cycles later in the anti-
CD3 stimulated, re-stimulated and non-re-stimulated populations.  
Figures 16a and b show that when GAPDH is detected at later cycles (~33-35 
cycles), the target genes Peli1 and RNF125 are not detected in the anti-CD3.28 re-
stimulated and non-re-stimulated populations.   
These results imply that the gene expression may have been detectable either after 
45 cycles into the PCR reaction, or if the T-cell subsets were purer. 
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Quantitative RT-PCR (Figure 17) was performed to detect the expression of E3 
ubiquitin ligase genes in anergic and non-anergic CD4+T-cell populations, to assess 
whether E3 ligase gene expression was specific to the function of either of these T-
cell subsets (Figure 15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17- Graphs comparing E3 ubiquitin ligase expression between anti-CD3 
stimulated and anti-CD3.28 stimulated conventional CD4+T-Cells +/- CD3.28 
Dynabead re-stimulation, measured by quantitative RT-PCR (n=2/3 except 
where there are no error bars in which case n=1). These T-cells were put 
through the anergy assays and frozen 3 hours after re-stimulation for PCR 
analysis. (a + b) represent the same experiment repeated using different 
donors. Each condition was repeated in triplicate and displayed as a mean. The 
error bars represent the SEM. The single lines on the graph represent where 
the gene was Not Detectable (N/D), where the reference gene GAPDH was 
detected however the target anergy gene was not. (#) indicates that there was 
insufficient material in these wells as the GAPDH reference gene was low and 
appearing late at ~34 cycles.  
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In Figure 17, when E3 ubiquitin ligase genes were detectable, the expression was 
very low. Higher expression of Cbl-b and Peli1 was found in CD3.28 re-stimulated 
populations in Figure 17a. Nedd4 and RNF128 were expressed at a higher level in 
the anti-CD3 re-stimulated population compared to the anti-CD3.28 re-stimulated 
population in Figure 17a. 
 
In Figure 17b the majority of the genes were undetectable. Overall gene expression 
in this experiment was higher compared the donor used in Figure 17a based on the 
average 2^-Δct values. Peli1 and RNF125 were expressed in the anti-CD3 
stimulated, non-re-stimulated population. ITCH was expressed in all four cell subsets 
in Figure 17b with the anti-CD3 re-stimulated and anti-CD3.28 non-re-stimulated 
populations showing the highest expressions.  
 
Results show that anergy may be broken in some donors upon CD3.28 bead 
stimulation, and expression of E3 ubiquitin ligase genes in different T-cell subsets 
may donor dependant.  
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4. Discussion 
The aim of this study was to investigate the E3 ubiquitin ligase expression in different 
CD4+T-cell subsets. Previous studies indicate that some E3 ubiquitin ligases 
contribute to T-cell anergy(10, 20, 23). This study replicates previously described 
anergy induction methods and compares E3 ubiquitin ligase expression in different T-
cell subsets using quantitative RT-PCR.  
4.1. The effects of different initial stimulation methods on T-
cell proliferation   
 
Different methods of initial anti-CD3.28 stimulation were used to determine which 
method would be best to use in the 8 day anergy assay. It was essential that the 
initial stimulation activated the conventional CD4+T-cells effectively whilst allowing 
them to return to rest prior to re-stimulation at day 4. This would prevent excessive 
‘boosting’ of existing T-cell proliferation upon re-stimulation.  
 
Figure 9 shows that anti-CD3.28 antibody is the best method to use to initially 
stimulate conventional CD4+T-cells. This is because T-cell proliferation induced by 
antibody stimulation is still significantly higher compared to the resting population at 
day 4, demonstrating that the T-cells have been activated, but are able to come back 
down to rest. On the contrary, Treg bead and Dynabead stimulation hyperactivate the 
T-cells which causes significantly higher levels of T-cell proliferation, preventing the 
T-cells from returning to rest at day 4.  
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4.2. The effects of different re-stimulation methods on anergy 
induction 
 
Previous results show that anergy is reversible with strong stimuli(10). It is possible 
that re-stimulation with anti-CD3.28 Dynabeads is too strong, and breaks anergy. In 
order to address whether Dynabeads were ‘breaking’ anergy, various methods were 
used to re-stimulate the T-cells (Figure 10). 
 Interestingly, the antibody re-stimulated population displayed similar levels of 
proliferation to the resting population, suggesting that mAbs may not be efficient at 
re-stimulating CD4+T-cells. Previous literature shows that plate bound anti-CD3 is 
more effective than soluble anti-CD3 at cross-linking and inducing strong T-cell 
activation(32). It is possible that anti-CD3 mAb was not bound to the plate efficiently 
causing signal 2 to be absent upon re-stimulation. This would cause T-cell stimulation 
through anti-CD28 alone which has been linked to T-cell apoptosis(33, 34), therefore 
explaining the lower number of antibody re-stimulated populations compared to non-
re-stimulated populations. It is also possible antibody re-stimulation re-stimulated the 
T-cells, but not strongly, allowing them to return to rest by Day 8,  
 
4.3. Inducing anergy in conventional CD4+T-cells 
The higher level of proliferation in some of the the anti-CD3.28 stimulated re-
stimulated populations compared to anti-CD3 stimulated re-stimulated populations 
shown in Figure 12a, may indicate that the anti-CD3 stimulated population is anergic 
upon re-stimulation. However, conflicting results from Figure 12a Experiment 4 and 
12b show that the initially unstimulated population has a similar number of 
proliferating T-cells compared to the anti-CD3 stimulated population.  
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It is possible that the unstimulated T-cell population is unhealthy indicating that the 
anti-CD3 stimulated population may be truly anergic. Figure 13 demonstrates that the 
number of non-proliferating cells from Experiment 4 is lowest in the resting population 
indicating that unstimulated T-cells require additional factors other than media alone 
to survive. The reduced health of the resting unstimulated population is reinforced in 
Figure 11, where the resting, re-stimulated population shows the lowest T-cell 
proliferation and high T-cell death. This data suggests that the resting re-stimulated 
T-cell population is dying or non-functional, indicating that the anti-CD3 stimulated T-
cells may be anergic upon anti-CD3.28 re-stimulation. 
Figure 11 shows that T-cells which receive anti-CD3.28 stimulation survive better and 
proliferate more compared to those which receive anti-CD3 stimulation. This may be 
because dual stimulation through CD3 and CD28 fully activated the T-cells, causing 
them to continue proliferating at day 4. Re-stimulation at day 4, may have ‘boosted’ 
the existing proliferation, causing the high T-cell proliferation number at day 8.  On 
the contrary, anti-CD3 stimulation may only provide few survival signals, therefore 
partially activating T-cells causing fewer T-cells to survive. To ensure all results were 
comparable, the samples were all run on the flow cytometer for the same length of 
time.  
Figure 11a shows variability in results between experiments, which may be due to 
biological variability between donors. T-cells from some donors may have been more 
susceptible to anergy induction and less able to survive in conditions without survival 
signals.  
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4.4. Comparing E3 ubiquitin ligase expression between Tregs 
and Conventional CD4+T-cells 
 
Tregs represent a small population of the total CD4+T-cell population making them 
difficult to isolate(8). Figure 14 demonstrates although the isolated population is 
enriched with Tregs, it is not as pure as it could be. It is possible that the 
contaminating CD4+CD25- cells may have therefore affected the results when 
measuring the E3 ubiquitin ligase expression of Tregs.  
 
Peli1 has a role in negatively regulating T-cell activation and is known to prevent 
autoimmunity(27). Peli1-/- T-cells in vitro demonstrate hyper-responsiveness to 
CD3.28 stimulation(27). However studies also show that Peli1 deficiency does not 
impair Treg cell development(27). This supports Figure 15 where there is no 
significant difference in Peli1 expression between Tregs and conventional T-cells.  
Peli1 has also been identified as having high expression in lymphocytes(27). Results 
from Figure 15 shows that Peli1 has the highest expression in conventional T-cells 
and Tregs compared to other E3 ligase gene tested.  
GRAIL (RNF128), Cbl-b and ITCH have all been reported to play a role in peripheral 
tolerance(24, 35-37). One study made links between the expression of FOXP3, ITCH 
and Cbl-b mRNA with CTLA-4 expression on the surface of CD4+CD25 high T-cells 
in MS(24). Furthermore, Cbl-b and ITCH activity in particular plays a role in Treg 
development by modulating parts of the TCR and interfering with TGFβ signalling(35) 
 
Data from Figure 14 demonstrates expression of Cbl-b, RNF128 and ITCH in Tregs 
compared to conventional CD4+T-cells where these genes were not detectable. This 
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shows that some E3 ubiquitin ligase expression may be upregulated in Treg cells 
therefore possibly contribute to their role in peripheral tolerance.  
 
The overall expressions of all the E3 ubiquitin ligase genes tested were generally all 
low and in some cases not detectable. In order to gain robust data where accurate 
conclusions can be drawn, the assays and PCR must be repeated using purer 
samples with more material.  
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4.5. Comparing E3 ubiquitin ligase expression between 
anergic and non-anergic CD4+T-cells 
 
Many tested samples shown in Figure 17a had insufficient material (#) therefore 
accurate Ct values could not be collected. Consequently, an accurate conclusion 
could not be drawn from these results. Where E3 ubiquitin ligases were expressed in 
certain subsets, this expression was extremely low. In order to try and make accurate 
comparisons, the PCR was repeated using samples from a different donor (Figure 
17b). 
It was previously mentioned that anergy can be broken with strong stimuli(10). Peli1, 
ITCH and RNF125 expression were found in in anti-CD3 stimulated, non-re-
stimulated cells, but were mostly undetectable upon re-stimulation. This suggests 
that anergy may have been broken due to strong re-stimulation therefore causing the 
T-cell to return to a normal activated phenotype. This would explain why these E3 
ligase genes fell to an undetectable expression level.  
 
Nedd4 is a positive regulator for T-cell activation(10, 20). In Figure 17b, Nedd4 
expression is higher in anti-CD3 stimulated, re-stimulated populations than non-re-
stimulated populations, which further indicates that the anergic state of the T-cells 
may be broken following re-stimulation.  
 
The differences in gene expression between both PCR experiments could be 
explained by biological differences between donors. T-cells may react differently to 
anergy induction depending on the donor and therefore may demonstrate different 
expression of E3 ubiquitin ligase genes.  
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4.6. Future work 
Anergic cells can be characterised by their reduced ability to proliferate, however 
previous studies also look for anergy induction by testing for reduced cytokine 
production such as IL-2, IL-3 and IFNɤ(10, 20). In future assays the cytokine 
production between anti-CD3 stimulated and anti-CD3.28 stimulated T-cells can 
be compared using cytokine secretion assays. This would confirm the anergic 
properties of the anti-CD3 stimulated T-cells. Anergy can also be reversed by 
adding exogenous IL-2(10, 17, 20). The expression of E3 ubiquitin ligase genes 
can be compared before and after IL-2 addition to define whether the gene 
expression changes with reversal of anergy. 
 
The majority of previous studies used plate-bound anti-CD3 to induce anergy in 
jurkat cell lines and murine T-cells. However, the current study used the same 
method to induce anergy in CD4+T-cells isolated from human peripheral blood. 
Previous studies demonstrated anergy induction in vitro using alternative methods 
such as mitogen concanavalin A, stimulation with the calcium ionophore 
ionomycin, MHC II-peptide complexes presented on a planar lipid bilayer, or 
peptides presented by APCs lacking B7 expression(10, 17, 18). It is possible that 
these alternative methods would be more efficient at inducing anergy in CD4+T-
cells isolated from human peripheral blood. 
 
Past experiments also used thymidine incorporation to measure T-cell 
proliferation, whereas the current study used cell proliferation dye. Previous 
studies show that thymidine can disturb cell generation cycles(38). The difference 
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in methods when measuring T-cell proliferation may explain why it was difficult to 
replicate past results in this study. 
 
A large proportion of T-cells died throughout the assay, making the cDNA recovery 
at the end of the assay minimal, therefore affecting the PCR and detection of E3 
ligase expression. To avoid this problem, future assays would involve the isolation 
of larger cell numbers to ensure that there is enough material. Furthermore, the 
purity of the Treg population can be increased by using FACS following magnetic 
isolation. This would prevent CD4+CD25- cells from contaminating the sample and 
affecting the PCR data.  
 
Other E3 ubiquitin ligases such as TRAF6, MARCHVII and AIP2(28, 39) have also 
been reported to play a role in anergy and T-cell activation. It is possible that these 
genes are also differentially expressed in different T-cell subsets and so the 
expression of these genes in different T-cell subsets should be tested in future. 
Furthermore, differential expression of E3 ligases may occur between other 
subsets of CD4+T-cells such as central memory and effector memory groups 
which may relate to their specific functions. This is another possible area of future 
research.  
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4.7. Conclusion 
 
The results from the anergy assay demonstrate that anergy in T-cells may be induced 
via stimulation through plate-bound anti-CD3 antibodies, however further work would 
need to be performed to confirm the anergic state of these T-cells.  
 
Unfortunately, accurate conclusions could not be drawn from the PCR data when 
comparing E3 ubiquitin ligase expression between T-cell subsets due to insufficient 
material and possible contamination of other T-cell subsets. In future, these challenges 
should be addressed so robust data may be collected and accurate conclusions 
drawn. 
 
By understanding the role of specific E3 ligases in T-cell activation and different T-cell 
subsets, signalling pathways and consequent E3 ligase expression can possibly be 
manipulated therapeutically in the future. By manipulating E3 ligase expression to 
induce T-cell anergy, you may prevent the development of autoimmune diseases, 
allergic responses and immune responses after transplantations. It may also be 
possible reduce expression of E3 ligases which negatively regulate T-cell activation, to 
encourage non-responsive T-cells to become more activated. These active T-cells 
may then be able to target cancers and chronic infections, where T-cell activation may 
otherwise be impaired.  
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